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ABSTRACT 
Molecular Markers of drug resistance and clinical outcome in falciparum malaria in 
Cambodia and the Democratic Republic of Congo 
(under the direction of Steven R. Meshnick) 
 
Background. Drug resistance is a major obstacle to the control of Plasmodium falciparum 
malaria. Monitoring the efficacy of antimalarials is a critical component to malaria control. 
One possible surveillance method is to use molecular markers. However, their relationship 
with clinical resistance needs to be established before they can be used.  
Methods. Clinical samples from an in vivo efficacy study of sulfadoxine-pyrimethamine 
(SP) based therapy in Rutshuru, Democratic Republic of Congo were used to estimate the 
effect of  mutations in dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) on
treatment failure. In addition, clinical samples from an in vivo efficacy study of mefloquine-
artesunate in Pailin, Cambodia were used to estimate the effect of changes in the P. 
falciparum multidrug resistance-1 (pfmdr1) gene on recrudescence. Lastly, a cross-sectional 
survey of Cambodia was conducted to determine the geographic distribution of the genetic 
changes in pfmdr1.
Results. In Rutshuru, the effect of mutations at dhps-437 and dhps-540 on SP treatment 
failure differed by level of parasitemia: for children with low parasitemia, the presence of 
both mutations was associated with a 17% (95%CI: -3%, 36%) greater absolute risk of 
treatment failure compared to having neither mutation (baseline risk: 21%). For children with 
high parasitemia, the risk difference was 50% (95%CI: 35%, 64%;  baseline risk: 8%). In 
Pailin, pfmdr1 copy number was strongly related to time to recrudescence after mefloquine-
iv
artesunate treatment (adjusted HR = 7.91, 95%CI: 2.38, 26.29). In the cross-sectional study 
of Cambodia, increased pfmdr1 copy number was found not only in Pailin, where mefloquine 
resistance has been well documented, but also in Chumkiri, an area not previously known for 
drug resistance.  
Conclusion. These studies demonstrated dhps mutations are associated with SP treatment 
failure in the DRC and pfmdr1 copy number is associated with recrudescence after 
mefloquine-artesunate treatment in Cambodia. The cross-sectional study demonstrates how 
the use of a molecular marker can be operationalized to detect resistant areas outside of 
current sentinel surveillance sites. Detecting dhps mutations in DRC and pfmdr1 copy 
number in Cambodia are potentially cost-effective methods to complement the current in 
vivo efficacy monitoring of drug resistance in these countries. 
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CHAPTER I: 
REVIEW OF MALARIA AND DRUG RESISTANCE
2MALARIA BIOLOGY 
Malaria is a mosquito-borne illness caused by parasites in the genus Plasmodium. The 
main Plasmodium species that infect humans are: P. falciparum, P. vivax, P. ovale, and P. 
malariae. P. falciparum infection is the most common and the most lethal.  
P. falciparum has a complex life cycle (Figure 1.1). An infected mosquito injects 
sporocytes into the human host during a blood meal. The sporocytes travel to the liver, where 
they infect hepatocytes. The parasite rapidly divides, which eventually causes the hepatocyte 
to lyse. Merozoites are released into the circulation, where they infect red blood cells (RBCs) 
and transform into trophozoites. The trophozoites divide into merozoites, which are released 
upon lysis of the RBC. Then the merozoites infect other RBCs. A small percentage of 
trophozoites mature into gametocytes, which are infectious to mosquitoes. When a mosquito 
takes a blood meal on an infected host, gametocytes are ingested as well. In the gut of the 
mosquito, the gametocytes undergo sexual reproduction to form sporocytes, which migrate to 
the salivary glands of the mosquito. At this point, the mosquito is considered infectious and 
is capable of transmitting the sporocytes to a human during their next blood meal (1). 
Malarial infections are often multiclonal, which means there is more than one genetically 
distinct clone in an infection. Multiclonal infections can be caused by presence of multiple 
clones in a mosquito or being bitten by more than one infected mosquito. Infections with 
more than 10 clones do occur, but most infections have 1-3 clones. There are more 
multiclonal infections in areas of high malaria transmission compared to low transmission 
areas. 
3PUBLIC HEALTH IMPACT OF FALCIPARUM MALARIA 
Falciparum malaria is a significant public health problem in the developing world. 
Approximately 40% of the world’s population is at risk of malaria (2). Control efforts have 
eliminated malaria from temperate areas but have been largely unsuccessful in tropical areas. 
In 2002, there were over 500 million clinical cases of Plasmodium falciparum (3). Most of 
these clinical cases occurred in Africa (70%) and Southeast Asia (25%) (3).  
Each year, approximately 1 million people die of P. falciparum malaria, most of which are 
African children (4). Malaria is the leading cause of death in children in sub-Saharan Africa: 
approximately 18% of all child deaths in this region was attributed to falciparum malaria in 
2000 (5).  
Falciparum malaria is also a significant source of morbidity. In children, malaria infection 
can lead to chronic anemia, malnutrition, and impaired growth (6-8). Cerebral malaria can 
cause long-term neurological and cognitive impairment, including deficits in memory, 
attention, and language (9). Malaria in pregnant women can lead to intrauterine growth 
restriction and preterm birth, which are both risk factors for infant mortality (10).  
EPIDEMIOLOGY OF FALCIPARUM MALARIA 
The epidemiology of malaria differs significantly by the endemicity of the region. In 
hyperendemic areas, the risk of having a symptomatic illness is highest in children between 
the ages of 6 months and 5 years (11). Adults rarely have severe disease (because the 
development of partial immunity). One exception is pregnant women, who are susceptible to 
strains of P. falciparum that bind to the placenta (12). In hypoendemic regions, there is less 
development of immunity, and as a result, malaria causes clinical disease in all age groups.    
4The epidemiology of falciparum malaria is also influenced by the vector. Anopheles 
mosquitoes transmit malaria. The particular species involved in transmission differs by 
region and also might change by season. Each species differs slightly in behavior, habitat and 
transmission efficiency, which in turn influence malaria dynamics. The main species 
complexes involved in transmission in Africa are: A. gambiae, A. arabiensis, A. funestus, A. 
nili, and A. moucheti (13). The most common vector, A. gambiae, lives and feeds around 
human settlements. It feeds mostly in the evening and at night. The amount of standing water 
and the density of animals will influence the mosquito population, and in turn will influence 
malaria dynamics.  
In Southeast Asia, the major vectors are A. dirus and A. minimus, which are located in 
forest and forest-fringe areas, respectively (14). The geographic distribution of falciparum 
malaria in this area can be partially explained by forestation. In addition, traveling to the 
deep forest is associated with increased risk of malaria. 
 
CLINICAL PRESENTATION OF MALARIA  
P. falciparum malaria is predominately a febrile illness, though the fever may fluctuate. 
Other symptoms include headache, anemia, vomiting, and diarrhea. Repeated malaria 
infections promote the development of partial immunity (15). Infected individuals with 
partial immunity are either asymptomatic or experience mild clinical signs and symptoms.  
Malaria is diagnosed by detecting parasites in the peripheral blood, either through 
microscopy, rapid antigen tests, or PCR (16). The density of parasites in the blood 
(parasitemia) is the main prognostic indicator of clinical outcome.  
5Severe malaria is defined as having any of the following conditions: hyperparasitemia 
(>100,000 parasites / µl in hypoendemic regions and >200,000 parasites / µl in hyperendemic 
regions), impaired consciousness, respiratory distress, or severe anemia (17). 
 
DRUG RESISTANCE: DEFINITION AND CLINICAL MANIFESTATION  
The technical definition of antimalarial drug resistance is “the ability of a parasite strain to 
survive and/or multiply despite the administration and absorption of a drug given in doses 
equal to or higher than those usually recommended but within tolerance of the subject” (18). 
To definitively prove that an infection is resistant to therapy, either adequate  levels of the 
drug in the blood have to be demonstrated or resistance of the isolate has to be confirmed in 
vitro. The falciparum strain present after treatment also has to be shown to be identical to the 
strain present before treatment (16).  
However, many P. falciparum infections are neither fully resistant nor completely 
sensitive to antimalarial drugs (19). Therefore, it is more useful to view resistance as a 
gradient of increasing tolerance of the parasite to the antimalarial drug. 
The normal response of a P. falciparum infection to treatment with an effective 
antimalarial is the abatement of fever and the disappearance of parasites within three days. 
The first sign of increased resistance is the delayed clearance of parasitemia. Moderate 
resistance is characterized by an initial disappearance of parasitemia followed by the 
reappearance of parasites after the concentration of the antimalarial has decreased to below 
the IC50 (20). Antimalarial drugs vary considerably in half-lives, and therefore the time 
before the reappearance of parasites varies as well; SP failures appear 7-28 days after 
6treatment while mefloquine failures appear up to 63 days after treatment. A high level of 
drug resistance manifests as no parasite clearance after treatment.  
The clinical manifestation of drug resistance is influenced by immunity. Older children 
and adults are more likely to clear resistant parasites than younger children because of the 
higher level of immunity (21). Therefore, in Africa and other highly endemic areas, clinical 
studies of antimalarial resistance are often restricted to children under 5 years of age. 
It is important to note that in vivo treatment failure can be caused by factors other than 
drug resistance, such as inadequate dosing or absorption, lack of adherence, vomiting, lack of 
immunity, and the acquisition of a new infection (22). 
 
ANTIMALARIALS AND THE HISTORY OF DRUG RESISTANCE 
Chloroquine 
Chloroquine was widely used for treatment and prophylaxis in the second half of the 20th 
century. This drug is cheap, effective, and causes few side effects. Resistance was first 
recorded in South America and the Thai-Cambodian border in the late 1950’s (23). 
Chloroquine resistance also developed independently in Paupa New Guinea and a second 
time in South America (24). Chloroquine resistance spread from these four loci to much of 
the world. In 2000, chloroquine resistance was present in almost all countries with 
falciparum malaria (25).  
In Malawi, there has been a re-emergence of chloroquine-sensitive falciparum malaria 10 
years after chloroquine was stopped being used (26). As a result, the re-introduction of 
chloroquine (in combination with artesunate) is currently being considered in Malawi. 
7Sulfadoxine-Pyrimethamine  
Sulfadoxine-pyrimethamine (SP) was the main replacement of chloroquine in Southeast 
Asia and Africa. Resistance to this combination emerged quickly: resistance was documented 
in Southeast Asia one year after its introduction (27). While moderate SP resistance has 
multiple origins, all parasites with a high level of SP resistance come from a single origin in 
Southeast Asia (28, 29). 
In Cambodia and Thailand, the rapid emergence of SP resistance made this drug unusable 
by the 1980’s. Even though SP has not been used in this area for over 20 years, recent 
surveys found that the parasites have remained resistant (30, 31).  
In Africa, moderate SP resistance is widespread, with a few pockets of high SP resistance 
(27). The median SP failure rate in Central and South Africa is around 8.9% while the 
median for Western Africa is slightly lower (32). However, 14-day failure rates greater than 
30% at one or more sites have been reported from Tanzania, Rwanda, Burundi, Kenya, and 
Liberia (33-35).  
 
Mefloquine  
Mefloquine has predominately been used in Southeast Asia and South America. In 
Southeast Asia, mefloquine was first used in the 1980’s in combination with SP. Mefloquine 
resistance was documented a few years later at the Thai-Cambodian border (36). Mefloquine 
resistance then spread to the Thai-Burmese border (14, 37). The decreasing efficacy of 
mefloquine prompted policy makers to increase the recommended dose of mefloquine and 
later to combine mefloquine with artesunate (38). On the Thai-Burmese border, the efficacy 
of mefloquine-artesunate has remained high since its introduction in 1994 (37). The 
8incidence of malaria in this region has also declined, possibly due to in part of the 
effectiveness of this combination. The mefloquine-artesunate combination has had less 
success on the Thai-Cambodian border. A recent study found that the 28 day failure rate was 
over 20% in this area, which suggests resistance is still a problem (39).  
 
Amodiaquine 
Little is known about resistance to amodiaquine. Amodiaquine has not been used that 
extensively in the past, however, many African countries have recently switched to 
amodiaquine-combination therapies (32). Clinical resistance to amodiaquine has been 
documented: in Rwanda, amodiaquine monotherapy had >25% 28-day failure rates two years 
after the implementation of-SP for the treatment of uncomplicated malaria (40).  
 
Artemisinin compounds 
Clinical resistance to an artemisinin compound, such as artesunate, has yet to be 
documented (41). These compounds are rarely used in monotherapy for the treatment of 
uncomplicated malaria because they are not as efficacious as the other antimalarials and 
often require multiple doses.  
Plasmodium falciparum clinical isolates with decreased sensitivity to artesunate and 
artemether has been documented in Central African Republic, Senegal, and French Guiana 
(42, 43). In addition, genetically stable P. chabaudi clones have been developed with 15 
times greater resistance to artesunate (44). These two pieces of evidence suggest Plasmodium 
spp. is capable of developing a high level of resistance to this class of compounds. Therefore, 
it is not a question of whether resistance will emerge but when will it occur.  
9STRATEGIES FOR COMPATING DRUG RESISTANCE  
One of the main strategies employed to impede the emergence of drug resistance is 
combination therapy. By simultaneously using two drugs with independent modes of action, 
the probability of the parasite evolving resistance to both drugs is dramatically decreased 
(45). In addition, certain drugs are synergistic, and therefore the efficacy of the combination 
is greater than either drug alone. 
The main partner drug using in combination therapies is artesunate. Artesunate is a very 
potent antimalarial with a rapid half-life that causes a dramatic drop in parasite levels (20). It 
is not that effective at curing malaria on its own, but increases the efficacy of other 
antimalarials when given in combination (46). In addition, artesunate is gametocydal, which 
decreases the transmissibility of malaria and slows down the transmission of drug resistant 
strains.  
Another key element to a successful program to fight drug resistance is the monitoring and 
evaluation of drug efficacy (18, 47). To decrease the impact of drug resistance on the 
morbidity and mortality of malaria, policy makers need to make informed decision in a 
timely manner about when to switch antimalarial regiments and what combinations should be 
used next. This can only be accomplished if they have access to current data on the 
effectiveness of antimalarials. 
 
IN VIVO EFFICACY STUDY 
The gold standard in monitoring parasite resistance is the in vivo test. This study involves 
recruiting symptomatic and parasitemic patients, treating them with the drug of interest under 
10
observation, and following them for 14-63 days for evidence of treatment failure (i.e. return 
of asexual parasites) (17). The World Health Organization (WHO) has standardized the 
protocol, which varies slightly by the endemicity of the region and the drugs being tested (17, 
48). The in vivo efficacy study is used not only to assess the current regimen, but also to 
determine the efficacy of potential replacement regimens. 
The main outcome of the in vivo efficacy study is treatment failure, which is defined as a 
worsening of the disease or the recurrence of parasites (Table 1.1). Treatment failure is 
classified according to when the treatment failure occurred (early: within 3 days; late: after 3 
days) and whether the subject was symptomatic (clinical: presence of fever or signs of severe 
disease; parasitologic: no fever or signs of severe disease).  
The main advantage of the in vivo efficacy study is that the results are easy to interpret and 
they appeal to policy makers (49). However, there are numerous disadvantages to these 
studies. First of all, treatment failure is a rough measure of clinical resistance. Most cases of 
treatment failure are caused by drug resistance but there are many other contributing causes 
(i.e. inadequate drug absorption or rapid elimination) (32). In addition, the results are not 
always applicable to the general population. For example, these studies often take place in 
areas with adequate health facilities, which are not always representative of a region. In 
addition, people with severe malaria, who are pregnant, or have infections mixed-species 
infections, are excluded. An additional disadvantage of the in vivo study is they are time-
consuming, especially when a 42-day follow-up is needed.  
One of the major complication of the in vivo efficacy study is that reoccurrence of 
parasites can be caused by both treatment failure (recrudescence) and a new infection. The 
classic way to distinguish between these two possibilities is the Snounou method. This 
11
approach involves genotyping three variable genes (msp-1, msp-2, glurp) through size-
fractionation (50). The appearance of a variant not seen in the enrollment sample is often 
interpreted as a re-infection while no new variants is considered recrudescence. Even though 
this method is the standard in the field, the validity of this method has been questioned.  For 
example, there are multiple ways to interpret the results. While some investigators consider a 
a re-infection as the appearance of a new variant irrespective if the recurrence sample 
contains variants seen in the original sample, others consider a re-infection when the 
recurrence sample does not contain any of the variants in the original infection (51). This 
technique has also been shown to underestimate the genetic complexity of infections (52). 
Therefore, the second infection might appear genetically identical to the enrollment sample 
when in fact they are different.  
Distinguishing between recrudescence and re-infection is more important in areas in high 
transmission areas and when the study has a long follow-up period because these factors are 
associated with increased risk of re-infection. The current WHO recommendation is to 
conduct molecular analysis of infection/re-infection in studies with greater than 14 days of 
follow-up in high transmission areas and in studies with greater than 28 days of follow-up in 
low transmission areas (32). 
One of the main criticisms of the implementation of the in vivo efficacy study is that the 
follow-up time is too short (53). The WHO recommends follow-up periods of 28 days or 
greater for antimalarials with extended half-lives, such as SP, mefloquine, lumefantrine, 
amodiaquine, and chloroquine (17, 32). However, shorter durations of follow-up are used in 
practice. In Africa, the 14-day in vivo efficacy study for SP has been used extensively (17, 
34). The 14-day in vivo efficacy study clearly is underestimating the true treatment failure 
12
rate, as SP failures have been documented 28 days after treatment (54).  But the 14-day study 
is still useful in comparing resistance in different regions or over time. In addition, the results 
can be interpreted without molecular genotyping, as the risk of re-infection is low in the two 
weeks following treatment. 
Another criticism of the in vivo efficacy study is the use of a per protocol data analysis 
strategy (55). The per protocol strategy is analyzing the data after all subjects lost to follow-
up or excluded are removed from the dataset. Often 10% of the enrolled subjects are 
excluded or lost to follow-up, yet greater exclusion rates do occur (33). If these exclusions 
are related to the outcome, then the results may be biased and the resulting treatment failure 
rate may not reflect the true rate in the population.  
Per protocol analysis is even more of a problem when two different drugs are being 
compared (56, 57). Differential exclusion or loss to follow-up could be occurring in the in 
vivo efficacy study, as subjects who are feeling ill (possibly due to malaria) are more likely 
to return for their follow-up visit and also are more likely to take an antimalarial outside the 
protocol. To prevent these potential biases, in vivo efficacy studies should be analyzed either 
using intention to treat (which classifies all exclusions or losses to follow-up as treatment 
failures) or by conducting sensitivity analyses. 
 
IN VITRO METHODS 
In vitro tests involve culturing clinical samples in serial dilutions of drug to determine the 
IC50 (the concentration of the drug at which 50% of parasite growth is inhibited). An isolate 
is considered resistance when the IC50 is above a certain threshold. The main advantage of 
this technique is that it directly measures parasite resistance without being confounded by 
clinical characteristics. In addition, the actual mechanism of drug resistance does not need to 
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be known to measure resistance. However, this technique suffers from various flaws. First of 
all, the assay involves using radioactivity, which is not always available in developing 
countries. Samples with low parasitemias cannot be reliability assessed. Certain drugs, such 
as amodiaquine, exert their antimalarial effect partially through metabolites, which is more 
difficult to reenact in an in vitro system. Technical issues prevent some drugs (i.e. 
sulfadoxine) from being tested in this manner. Finally, due to selective forces resulting from 
culturing, the results do not always correspond to the actual situation in vivo (58). 
 
MOLECULAR MARKERS AS A PROPOSED SURVEILLANCE TOOL 
Molecular markers are genetic changes in the parasite that are associated with drug 
resistance. They have been established for many (SP, chloroquine, mefloquine, atovaquone) 
but not all (artesunate, amodiaquine) drugs used to treat falciparum malaria. New PCR-based 
technology has increased the capability and affordability of screening a large number of 
samples for these genetic changes. Therefore, using molecular markers for surveillance 
instead of in vivo tests could save considerable time and effort. In addition, since only small 
amounts of blood need to be collected and no follow-up is required, surveillance can be 
extended beyond sentinel sites. Processing clinical samples directly, instead of culturing 
them first, eliminates the bias created from the selective pressure from culturing samples.  
However, using molecular markers for monitoring drug resistance has at least three 
disadvantages. First, molecular markers have not been identified for all drugs. Second, drug 
resistance in a parasite is often caused by more than one genetic change and therefore just 
looking at one marker might not accurately represent drug resistance. Third, the use of 
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molecular markers for surveillance needs to be validated with clinical data before the results 
can be interpreted correctly. 
 
RELATIONSHIP BETWEEN MOLECULAR MARKERS AND RESISTANCE: 
SUMMARY OF THE LITERATURE 
Molecular markers of resistance have been investigated for several antimalarials. Potential 
molecular markers are often first identified by sequencing of clinical isolates or by 
performing genetic cross between different laboratory strains and identifying the genetic 
changes that segregate with drug resistance traits. The relationship between molecular 
markers and in vivo treatment failure is then investigated to determine if the molecular 
markers confer clinically relevant resistance. Table 1.2 lists the genes that have been 
proposed as potential molecular markers. The literature supporting most of these molecular 
markers is summarized below. 
 
Chloroquine 
Chloroquine resistance has been strongly linked to genetic changes in the Plasmodium 
falciparum chloroquine resistance transporter (pfcrt) (24). pfcrt’s function is not fully known, 
but one hypothesis is that pfcrt is a transporter in the digestive vacuole membrane (59). A 
mutation at codon 76 appears to be the key determinant of chloroquine resistance, though 
changes at codons 72, 74, 75, and 220 are also important (60). Chloroquine resistance is 
further modulated by changes in the Plasmodium falciparum multi-drug resistance gene-1 
(which is described further under molecular markers of mefloquine resistance). 
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Numerous  clinical studies have demonstrated that pfcrt-76 and pfmdr1-86 are related to 
chloroquine treatment failure (61-64). For example, in Mali, the presence of the pfcrt-76 and 
pfmdr1-86 were independently associated with 14-day chloroquine treatment failure (pfcrt-
76: OR=16.1 95%CI: 5.7, 45.7; pfmdr1-86: OR = 2.5, 95%CI: 1.1, 5.8) (61). 
Sulfadoxine-Pyrimethamine  
Sulfadoxine and pyrimethamine inhibit dihydropteroate synthase (dhps) and dihydrofolate 
reductase (dhfr), respectively, which are two enzymes involved in folate biosynthesis (Figure 
1.2). Plasmodium spp. acquire folate primarily from de novo synthesis, though an exogenous 
folate salvage pathway can be utilized as well (65). 
SP resistance is conferred by point mutations in either enzyme, which sterically inhibit the 
binding of their respective inhibitor (65-69). Mutations in dhfr codons 51, 59, and 108 have 
been associated with pyrimethamine resistance (66, 69). The 108 mutation is the first to 
appear in an area where SP is being used (70). Additional mutations, which accumulate over 
time, have a synergistic effect on pyrimethamine resistance.   
Sulfadoxine resistance is associated with mutations in dhps at codons 436, 437, 540, 581, 
and 613 (67, 68). However, the role of the mutations at the 436 and 613 codons in conferring 
sulfadoxine resistance is controversial (65). As with dhfr, subsequent mutations in dhps
synergistically contribute to sulfadoxine resistance (68).  
The importance of the dhfr mutations in conferring pyrimethamine resistance has been 
documented in several in vitro studies (71-73). (Due to technical difficulties, in vitro 
susceptibilities to sulfadoxine cannot be reliably determined). The prevalence of dhfr and 
dhps mutations is also associated with the past SP usage in a region (74, 75).  
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The relationship between the presence of these mutations and in vivo resistance is more 
tenuous. Most studies have demonstrated an association between in vivo resistance and 
mutations in dhfr and dhps (71, 72, 76-90). Though three studies concluded that there was no 
association (72, 91, 92). Even in the studies that report an association, the strength of the 
association and the mutations having the biggest impact on resistance varies greatly. There 
are many reasons to explain these discrepancies. First of all, in vivo resistance depends on 
other factors beyond the resistance of the parasite, including the parasitemia (density of 
parasites in the blood) and age (which is a measure of the immune response) (21, 93). These 
potential confounders and effect measure modifiers vary by region and therefore could affect 
the apparent relationship between molecular markers and treatment failure. Half of the 
studies cited above are restricted to children between 6 months and 5 years while the rest 
vary greatly in the age distribution of the study population. Some studies don’t even mention 
the age eligibility criteria or the age distribution of the participants (85, 89).  
In addition, the association between the mutations and clinical resistance is dependent on 
the prevalence of both treatment failure and the mutations in a particular area. For example, 
Mockenhaupt et al. (2005) claim that dhfr but not dhps mutations are associated with 
treatment failure. However, the only dhps mutation observed was dhps-437 (86). Another 
possibility is that the effect of the mutations might be modulated by other parasite 
characteristics (such as the expression of dhfr or dhps), which might vary by region as well.  
Yet another possible reason for this discrepancy is that the coding of the dhfr and dhps
mutations varies greatly across studies. Some studies combine the haplotypes of dhfr and 
dhps while other studies test the two haplotypes separately. Still other studies look at 
individual mutations or the number of mutations. In addition, two studies excluded all 
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samples with mixed genotypes (71, 89) while the rest of the studies retained the mixed 
genotypes by coding them in a variety of ways. 
Many of these studies have methodological issues as well.  With a few exceptions (78, 82, 
84, 85, 90, 94), confounders and effect measure modifiers are not assessed. In addition, the 
most common analysis approach is to haphazardly try different combinations of the 
mutations and report ones (or emphasize those) with small p-values. This approach does not 
account for multiple comparisons and will tend to emphasize the largest effect instead of the 
most precise or valid estimate.  
In summary, many studies have investigated the relationship between dhfr and dhps
mutations and treatment failure (Table 1.3). The results vary greatly, partially due to 
differences in methodology and partially due to regional differences in the parasite and host. 
The estimate of the effect of mutations on treatment failure can be improved on by a 
systematic approach to screen and control for confounders and effect measure modifiers. In 
addition, the geographic variation suggests the relationship between molecular markers and 
treatment failure has to be established before they can be used for surveillance in a region. 
Mefloquine 
Mefloquine is a quinoline compound that is structurally related to chloroquine but has a 
longer half-life. Mefloquine’s mechanism of action has yet to be fully elucidated, but it 
probably involves blocking hemoglobin breakdown in the parasites’ food vacuole (95). 
Mefloquine drug resistance is associated with genetic changes in the pfmdr1 gene. This gene 
encodes for P-glycoprotein homologue-1 (pdh1), an ATP-binding cassette transporter, which 
is homologous to the multi-drug resistance transporters found in some human cancers (96). 
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Pgh1 has been localized to the membrane of the parasite’s food vacuole. The exact function 
of pgh1 and how it contributes to drug resistance are unknown but in vitro data suggest it is 
involved in drug efflux from the vacuole (96). pfmdr1 has also been associated with 
chloroquine and artemisinin resistance (97-101). 
In vitro studies have demonstrated that mutations at codons 86, 184, 1034, and 1042, along 
with the amplification of this gene, are associated with mefloquine resistance (97-99, 101, 
102). However, the genetic background of the parasite appears to modulate the effect of these 
mutations on resistance (102). Based on a theoretical structural model of pfmdr1, these 
codons are thought to be in the hydrophobic side of the protein and might modulate the 
transporter’s specificity (101).  
pfmdr1 copy number has been related to the increased mRNA expression of the transporter 
(103), and therefore might confer resistance by increasing the efflux of mefloquine from the 
food vacuole. Previous studies have found increased pfmdr1 copy number only in the 
presence of the wild-type genotype at 86, 1034, and 1042 codons (99, 104). There appears to 
be no relationship between the genotype at pfmdr1-184 and copy number.  
In vivo studies comparing pfmdr1 haplotype and copy number with treatment failure have 
been quite limited. Pillai et al. 2003 found that the genotypes at  pfmdr1 codons 1034, 1042 
and 1246 were not related to treatment failure to mefloquine and mefloquine-artesunate 
therapy in Peru (105). However, this conclusion is questionable, given that there were no 
treatment failures. A clinical study in Gabon found pfmdr1 haplotype was not related to ultra-
low dose mefloquine treatment failure (106). Yet the applicability of these results to standard 
doses of mefloquine is unknown. Two studies have demonstrated that increased copy number 
of pfmdr1, but not the aforementioned mutations, is associated with clinical resistance (104, 
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107). This relationship persisted when mefloquine was used in combination with artesunate 
(104). Both these studies took place in Western Thailand and therefore need to be replicated 
in other areas to determine if the results are generalizable.   
 
Amodiaquine 
Little is known about mechanisms of or molecular markers for amodiaquine resistance. 
Amodiaquine is structurally related to chloroquine. Resistance to these drugs is correlated in 
clinical isolates, which suggests the mechanism of resistance is similar (108-110). One study 
found an association between the pfcrt-76 mutation and amodiaquine resistance, though this 
observation was based on very few samples (111). 
 
Artesunate 
There is currently a debate about whether changes to pfmdr1 confer artesunate resistance. 
Most (97, 101, 102), but not all studies (112, 113) have demonstrated an association between 
pfmdr1 haplotype and artesunate IC50. Increased pfmdr1 copy number, when combined with 
the haplotype, is also associated with an increased IC50 to artemisinin-derivatives (98, 99). 
However, only small increases in IC50 were observed in these studies. One clinical study 
found that artesunate monotherapy did not select for pfmdr1 mutations (114).  Therefore, the 
increase in resistance conferred by changes in pfmdr1 might not be clinically relevant.  
In vitro artesunate resistance has also been associated with changes in the translationally 
controlled tumor protein (115) and a SERCA-type ATPase (116), but it is unclear if these 
changes are clinically relevant (43, 104). 
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MALARIA AND DRUG RESISTANCE IN CAMBODIA  
Despite a recent decline in incidence in the last 15 years, malaria remains a significant 
public health problem in Cambodia (117, 118). In 2003, there were over 70,000 reported 
cases of malaria and approximately 500 reported deaths (118). Since underreporting is likely, 
the burden of malaria is probably much larger. Most cases of malaria occur near the borders 
with Laos, Thailand, and Vietnam, while there are virtually no cases in urban areas (119, 
120). A majority (89%) of all cases of malaria are caused by P. falciparum; the rest of cases 
are caused by P. vivax (118). Malaria disproportionally affects ethnic minorities, plantation 
workers, gem miners, soldiers and refugees due to their close proximity to mosquito-filled 
forests. Malaria mostly affects adult men, as traveling into forested areas for work exposes 
them to malaria-infected mosquitoes. 
The Thai-Cambodia border is an epicenter of drug resistance. The second report of 
chloroquine resistance and the first report of pyrimethamine resistance came from this area 
(23). Mefloquine was first used in this region in combination with SP in the mid 1980’s (25). 
However, due to the high resistance to SP, this combination was eventually replaced by 
mefloquine monotherapy. Mefloquine efficacy declined rapidly in the next two decades (121-
123). The worst reports of mefloquine efficacy in the world came from this area in the early 
1990’s (121). In 1999, the national recommended treatment for uncomplicated P. falciparum 
malaria was changed from mefloquine to mefloquine plus artesunate in response to 
increasing levels of treatment failure in the western areas of the country.  
While Western Cambodia is a foci of drug resistance, parasites in the east have remained 
drug sensitive to chloroquine and mefloquine (119). A previous survey of molecular markers 
in Cambodia found that mutations in dhfr, dhps, and pfcrt are almost universal (31, 124). In 
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addition, most parasites had the wild-type genotype at pfmdr1 codons 86. 1034, 1042, and 
1246 while the 184 genotype was more variable (31).  
 
MALARIA AND DRUG RESISTANCE IN DEMOCRATIC REPUBLIC OF CONGO 
Malaria is significant cause of morbidity and mortality in children and pregnant women in 
Sub-Saharan Africa (125). In the DRC, malaria causes 30% of childhood mortality (126). 
There were over 4 million reported cases of malaria and 16,000 deaths in the DRC in 2003 
(126). Civil unrest has compounded the impact of this disease. The eastern part of the 
country has been the site of much turmoil: over 500,000 Rwandan refugees fled to this area 
in 1994 and 5 years later it was the foci of the civil war (127). In both of these crises, malaria 
was a significant source of morbidity and mortality (17, 127, 128).  
An in vivo efficacy study that was conducted in the refugee camp in 1994 documented 
moderate failure rates for both chloroquine and SP (129). However, malnutrition was highly 
prevalent in this population, and since malnutrition is a risk factor for treatment failure, the 
failure rates observed in this study likely overestimate the actual level of resistance (64, 130). 
Observers from the CDC noticed high failure rates of chloroquine in the refuge camps in 
Eastern Congo. As a result, in 1995 they implemented the use of SP for the treatment of 
uncomplicated falciparum malaria (P. Bloland, per. com.). 
With the building of a health infrastructure in the DRC in the past couple of years, more 
information on drug resistance in the country is becoming available. In a nation-wide survey 
conducted in 2000-2001, the overall failure rate for chloroquine and SP was 45.4% and 7.5%, 
respectively (131). There was substantial geographic heterogeneity in the efficacy of both 
drugs, with the eastern part of the country having a higher failure rate. In Bukavu, which is 
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near the Rwandan border, the chloroquine failure rate was 80% and the SP failure rate was 
9.3%. Because of the observed high failure rates of chloroquine, the national first line agent 
for the treatment of uncomplicated malaria was changed to SP in 2001. 
There have been no previous studies on the prevalence of molecular markers of drug 
resistance in the DRC. However, there have been prevalence studies in neighboring 
countries. In the Republic of Congo, where chloroquine remains the first-line treatment for 
uncomplicated malaria, a study in Brazzaville and Pointe-Noire found a high prevalence of 
the triple dhfr mutant (mutations at 51, 59, and 108) and the dhps-437 mutation but no 
mutations at dhps-540 (132). These results suggest that if the first-line treatment was changed 
to SP, it would initially be effective but resistance would emerge quickly. In Uganda, a 
nation-wide survey found the prevalence of samples with the quintuple mutation and the 
pfcrt-76 mutation varied between 61-91% (depending on the site) (133).  
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Table 1.1 Outcome classification of the in vivo efficacy study*
Outcome Abbr. Criteria
Early Treatment Fa ilure ETF one of the fo llowing:
--signs of severe malaria on day 1-3 in
the presence of pa rasitemia
--parasitemia on day 2 higher than on
day 0
--parasitemia on day 3 greater than
1/4th pa rasitemia on day 0
Late Clinical Failure LCF one of the fo llowing:
--signs of severe malaria on after day 3
in the presence of parasitemia
--presence of pa rasitemia after day 3
with axillary temp ³ 37.5  C
Late Parasitological Failure LPF --presence of pa rasitemia after day 3
with axillary temperature < 37.5  C
Adequa te Clinical and Parasitological Response ACPR --absence of pa rasitemia on day 14,
irrespective of axillary temperature
*according to the WHO protocol (17) 
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Table 1.2 Plasmodium falciparum genes that are potential molecular markers for 
antimalarial resistance*
Anti-malarial Gene 
Gene 
abbreviation
Quinine Plasmodium falciparum multidrug resistance gene-1 pfmdr1  
Chloroquine Plasmodium falciparum multidrug resistance gene-1 pfmdr1 
 Plasmodium falciparum chloroquine transporter pfcrt 
Mefloquine Plasmodium falciparum multidrug resistance gene-1 pfmdr1 
Amodiaquine Plasmodium falciparum chloroquine transporter pfcrt 
Lumefantrine Plasmodium falciparum multidrug resistance gene-1 pfmdr1 
Artemisinin compounds ATPase gene 6 atp6 
Sulfadoxine dihydropteroate synthase dhps
Dapsone dihydropteroate synthase dhps
Pyrimethamine dihydrofolate reductase dhfr 
Proguanil dihydrofolate reductase dhfr 
Atovaquone cytochrome b cytb 
*based on (43, 134). 
 
Table 1.3 Summary of studies investigating the relationship between mutations in dhfr and dhps and SP treatment failure
Follow-up PCR Confounders
Age
distribution
dhfr/dhps
associated What codons were
Location (days) corrected? controlled for of subjects* with TF‡? associated with TF? Ref.
Gabon 28 no 6m-10y no . (72)
Cameroon 28 yes all ages possible† dhfr-51,59,108 (71)
Lao PDR 14 no >1 year possible dhfr-51, dhps-436, 437, 613 (77)
Uganda 14 yes parasite density 6m-5y yes dhfr-59, dhps-437, 540 (94)
Uganda 28 yes age, parasite density 6m-5y yes dhfr-59, dhps-540 (78)
Sudan 28 no 10 - 65y yes dhps-436 (76)
Mozambique 28 no 6m - 5y yes dhps-437 (76)
Tanzania 14 no 6m - 5y yes dhps-437 (76)
Nigeria 28 yes <12 years yes dhfr-51,59,108, dhps-437, 540 (80)
Sudan 28 no 10-65 years possible dhfr-51, 108, dhps-436 (81)
Malawi 28 no hemoglobin 6m-6y yes dhfr-51,59,108, dhps-437, 540 (82)
Uganda 28 yes parasite density 6m-5y yes dhfr-59, dhps-437, 540 (84)
Tanzania 14 no 6m-5y yes dhfr-51,59,108, dhps-437, 540 (87)
Kenya 14 no Not mentioned yes dhfr-108, 59, dhps-437 (89)
Columbia 14 no Not mentioned no . (91)
Ghana 28 yes sex, parasite density, 6m - 5y yes dhfr-51,59,108 (86)
previous drug use
Uganda 14 yes 1-37 years possible dhfr-51,59,108 dhps-436, 437 (135)
Uganda 28 yes > 6 months yes dhfr-59, dhps-437, 540 (88)
Uganda 28 yes age, prior drug use 6m-5y yes dhfr-108, 59, dhps-437 (90)
Sri Lanka 42 no Not mentioned no . (92)
* in months (m) or years (y)
† The mutations appeared to be related to treatment failure yet the small sample size of these studies precluded the association from
achieving statistical significance
‡ Treatment failure
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Figure 1.1 Plasmodium falciparum life cycle*
*Reference: (136)
27
Figure 1.2 Folate biosynthesis pathway in Plasmodium falciparum*
GTP + 
pABA + Glu
DHPS H2-folate DHFR H4-folate
dUMP
dTMPDNA
-
Sulfadoxine
-
Pyrimethamine
exogenous
folate
*Adapted from (137). 
CHAPTER II: 
RATIONALE, OBJECTIVES, AND METHODS 
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RATIONALE  
Malaria is a major public health problem; in 2002, there were over 500 million clinical 
cases of Plasmodium falciparum malaria (3). Malaria is particularly devastating in 
developing countries with inadequate health infrastructures. For example, in the Democratic 
Republic of the Congo (DRC), one-third of all child mortality is caused by malaria (126). 
One of the greatest challenges in the control of malaria is drug resistance, which has 
contributed to its re-emergence and spread (27). Resistance to chloroquine is nearly universal 
while resistance to sulfadoxine-pyrimethamine (SP) and mefloquine is increasing.  
Monitoring drug efficacy is an important component to a national malaria control program. 
Only with recent and relevant data on the level of drug resistance, can policy makers decide 
what drug combinations should be used and what areas should be targeted for interventions. 
Currently, drug resistance is monitored with in vivo efficacy trials. However, these trials are 
time consuming, as patients need to be followed for 14-42 days. One alternative to the in 
vivo efficacy trial is to use molecular markers of drug resistance. These molecular markers 
have been identified though working with the parasite in culture. However, the effect of these 
genetic changes on in vivo treatment failure is less clear.  
 
OBJECTIVES 
The main purpose of this work is to estimate the relationship between molecular markers 
of resistance and clinical treatment failure in falciparum malaria. Three specific objectives 
will be addressed: 
1. To determine the relationship between genetic changes in parasites’ dihydrofolate 
reductase (dhfr) and dihydropteroate synthase (dhps) genes and clinical resistance to 
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SP-based combination therapy. To address this question, samples collected from an in 
vivo efficacy trial in Rutshuru, DRC have been genotyped for mutations in dhfr and 
dhps.
2. To establish the association between molecular markers in pfmdr1 and clinical 
resistance to mefloquine-artesunate therapy. To accomplish this aim, samples from an 
in vivo efficacy trial in Pailin, Cambodia were used. Clinical samples have been 
genotyped for four codons in pfmdr1 and the number of copies of pfmdr1 in the 
genome.  
3. To determine the geographic variation in the prevalence of molecular markers in 
Cambodia. In Cambodia, resistance to mefloquine increases from east to west.  
SPECIFIC HYPOTHESES 
1. Genetic changes in the dhfr and dhps gene in Plasmodium falciparum are associated 
with increase risk of SP treatment failure in Rutshuru, DRC. 
2. pfmdr1 copy number and genotype are associated with increase risk of recrudescence 
after mefloquine-artesunate treatment in Pailin Cambodia 
3. pfmdr1 copy number varies geographically in Cambodia. Specifically, pfmdr1 copy 
number is highest in the West (which is historically the focus of resistance).  
 
OVERVIEW OF METHODS 
 Clinical data and samples from three different studies were utilized in this dissertation. 
Ancillary studies were conducted on two in vivo efficacy trials in Rutshuru, DRC and Pailin, 
Cambodia. In addition, the main analysis for a cross-sectional study in Cambodia is included. 
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The methods for each study will be summarized below and will be expanded upon in 
subsequent chapters. Each study was a collaborative effort. The main collaborators and their 
contribution will be made clear in the beginning of each section.  
 
IN VIVO EFFICACY STUDY IN RUTSHURU, DRC 
Collaborators 
Walter Kazadi ran this trial for the Programme National de Lutte contre le Paludisme of 
DRC, in collaboration with Kutelemeni K. Albert and Antoinette Tshefu  (Kinshasa School 
of Public Health, DRC) and Peter Bloland (Centers for Disease Control, USA). Alisa Alker is 
responsible for all the laboratory work and all the data analysis.  
 
Study setting and population 
 Rutshuru is in the North Kivu district of the Democratic Republic of the Congo near the 
Ugandan and Rwandan border (Figure 2.1). Rutshuru has a long history of conflict: fighting 
occurred here during the 1993 civil war, Rwandan refugees fled to here in 1995, and the 
fighting in the most recent civil war occurred near by. Due to the political instability of this 
area, little is known about the epidemiology of malaria. The study participants came from the 
surrounding areas and where recruited a four different clinics around Rutshuru.  
 
Clinical Study 
A therapeutic efficacy trial in Rutshuru, DRC was conducted to compare the efficacy of 3 
regiments: 1. amodiaquine plus SP (AQSP); 2. artesunate plus SP (ASSP); and 3. SP 
monotherapy (SP). This trial was a randomized, open label study following the 14-day WHO 
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1996 protocol with the modifications suggested in the 2002 report (48, 138). The study took 
place between June and September 2002 at four different clinics.  
The inclusion criteria included: 1. between the ages of 6 months and 5 years; 2. did not 
suffer from severe malnutrition; 3. malaria infection with only P. falciparum species; 4. a 
parasitemia between 1,000 to 200,000 parasites / Rl; 5. absence of signs of severe disease, 
which included: prostration, impaired consciousness, respiratory distress, multiple 
convulsions and abnormal laboratory findings (17).; 6. axillary temperature equal or greater 
than 37.5 ºC; 7. absence of other fever-causing illnesses; 8. no previous reaction to sulfa-
containing drugs; 9. ability to return to clinic for follow-up visits; and 10. consent of the 
parent or guardian.  
At enrollment a brief clinical exam was administered and approximately 50 Rl of blood 
was collected. The blood was placed on IsoCode Stix filter paper (Schleicher & Schuell, 
Keene, N.H., USA), desiccated, and then transported to UNC Chapel Hill for processing. The 
subjects were randomized to a treatment arm and given their assigned treatment. Subjects 
randomized to the ASSP and AQSP received additional doses of artesunate or amodiaquine 
on the first and second day after enrollment.  
Follow-up visits were scheduled for days 1, 2, 3, 7 and 14 after enrollment. They were also 
encouraged to return to the clinic if the subject’s symptoms worsened. Subjects were 
excluded after enrollment if: 1. they were diagnosed with another illness that would prevent 
assessment of treatment outcome; 2. they could not be located for follow-up visits; 3. the 
parents or guardians withdrew consent; 4. they took another antimalarial beyond those given 
in the study protocol; or 5. non-falciparum malaria infection was detected. 
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The sample size of this study was calculated in order to estimate the population proportion 
of treatment failure, while taking in account loss to follow-up according to the WHO 
protocol (17). In all three arms, the confidence level was 95%, the precision was 10 
percentage points, and the loss to follow-up was assumed to be 10%. In the SP arm, with an 
expected failure proportion of 30%, the required sample size is 90. For the two combination 
arms,  an expected failure proportion of 20% would require a sample size of 80.  
249 children under the age of 5 were initially enrolled, though 17 (7%) patients were later 
excluded. Most of the exclusions were from lost to follow-up. An adequate clinical and 
parasitological response was observed in 39.4% of the subjects in the SP arm, 68.2% of the 
AQSP arm, and 78.9% of the ASSP arm. Three subjects died during the course of the study. 
The exact cause of death was not definitely determined, though in one case the suspected 
cause was a home-remedy for malaria.  
 
Collection of Clinical Covariates 
At enrollment, a brief clinical exam collected information on age, weight, axial 
temperature, and respiratory rate. A few drops of blood were collected to determine the  
parasite concentration and hemoglobin level. At all subsequent visits, axial temperature was 
collected. Parasite and gametocyte concentration was measured on all visits except for day 1. 
Z-scores of weight for age, which is a measure of malnutrition, were calculated in reference 
to the NCHS/WHO international dataset (139).  
Measuring the presence and concentration of P. falciparum parasites is important not only 
in assessing eligibility but also in determining the outcome. When the patient was being 
screened for eligibility, two slides were made from drops of blood: a thick smear and a thin 
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smear. Both were stained with Giemsa. To determine if the patient was eligible for the study, 
the thick smear was examined for the presence of P. falciparum asexual parasites and the 
relative number of parasites per leukocyte. At least 200 leukocytes were counted. The 
parasitemia was determined using the following formula: parasitemia (per Rl) = # of parasites 
* 8000 / # leukocytes (140). 100 different fields were examined to ensure the infection was 
not mixed or that it was truly negative. If the patient was enrolled in the study, the thin smear 
slides were read to obtain a more accurate measurement of the parasite density. 
 However, on the second reading of the slides, 18 (8%) people were found to have a 
parasitemia of greater than 200,000 parasites per Rl. These individuals were kept in the 
dataset because having a high parasitemia does not preclude the estimation of the effect of 
molecular markers on treatment failure. However, the inclusion of these subjects might make 
the results difficult to compare to other studies that followed the eligibility criteria more 
strictly.  
Diagnosis of malaria by thick-smear microscopy is the gold standard of the field and is 
used in most in vivo efficacy trials. While using PCR to detect infection does have increased 
sensitivity (141), developing countries do not have the infrastructure to support the use PCR 
in the treatment of patients. The sensitivity limit for using smear slides and microscopy is 8 
parasites per µl of blood (140). Since one of the eligibility criteria is having a parasitemia of 
>1,000 parasites per µl of blood, the limited sensitivity will not affect eligibility. However, 
since treatment failure is defined as the presence of parasites in the blood, there is the 
possibility of misclassification of people with low parasitemia as treatment successes.  
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Genotyping 
Out of the 249 children initially enrolled, 212 (85%) were available for genotyping. 
Samples were available for all the patients that were lost to follow-up or died. The genotyped 
subjects were more likely to be male, have higher parasitemias, and were more likely to 
experience treatment failure compared to the subjects that were not genotyped (Table 2.1). 
The results of t-test or chi-square test for comparing these two groups are presented in Table 
2.1. 
DNA was extracted according to the IsoCode Stix’s protocol. The samples were genotyped 
for 3 dhfr (51, 59, 108) and 4 dhps (437, 540, 581, 613) codons using a real-time PCR assay 
with minor groove binding (MGB) probes (142). The real-time PCR methods are presented 
in Appendix B. MGB probes consist of an oligonucleotide that is complementary to the 
sequence of interest, a fluorophore on the 5’ end and a quencher on the 3’ end. The binding 
between the oligonucleotide and sequence is very sensitive to single base differences (143, 
144). To achieve allelic discrimination, two probes are used: one specific to the mutant 
sequence and another specific to the wild-type sequence. The two probes are attached to 
different fluorophores (wild-type: FAM, mutant: VIC). During amplification, the probe that 
is complementary to the sequence contained in the sample will bind to the amplicon. When 
the DNA polymerase creates the complimentary strand, its innate 5’ nuclease activity will 
cause the fluorophore to be separated from the quencher, which allows it to fluoresce.  
The genotype of a sample can be determined by measuring the change in fluorescence 
during the PCR reaction: an increase in the FAM signal indicates the presence of the wild-
type sequence, an increase in the VIC signal indicates a mutant sequence and an increase of 
both signals indicates the sample is mixed. 
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These assays have a few limitations. There are two different mutant forms found in nature 
of dhfr-108 (Asn and Ser) and dhps-613 (Thr and Ser). The assays can detect both forms but 
cannot identify which mutant form is present. Another limitation is that the dhps-437 
mutation does not work in the presence of a mutation in codon 436. However, the dhps-436 
mutation, dhfr-108-Thr, and dhps-613-Thr are rare in Africa, and therefore should have a 
minimal impact on the genotyping of samples from Rutshuru.  
 Based on a limited number of samples (n = 5), the dhfr and dhps MGB assays were found 
to be 100% sensitive and specific when compared to sequencing (the gold standard) (142). In 
addition, the assay was able to detect a minor allele when it consisted of at least 10% of the 
sample. The detection limit ranged from 10 – 1,000 copies of the genome per reaction.  
 One complication in the genotyping of clinical samples is that many P. falciparum 
infection are multi-clonal. In addition, the relative concentration of clones varies on a daily 
basis (145). Therefore, at any particular codon, more than one genotype might be present. 
Once antimalarial therapy is initiated, the drug resistant strains will be selected for. Therefore 
the presence of these strains, not their relative concentration is most likely to be related to 
treatment failure. 
 Another difficulty is the determining the haplotypes present in a sample. The genotype at a 
single nucleotide polymorphism may be important, but the combinations of SNPs often 
interact in a complex manner to produce the phenotype. Therefore, in human genetics, a lot 
of effort is put into determining the haplotype (i.e. combination of SNPs) of both alleles.  P. 
falciparum is haploid for most of the lifecycle (and therefore each parasite will have only one 
allele). Yet the multiclonal nature of infections might make haplotype determination difficult. 
For example, if a sample was mixed at all three dhfr codons, it is unclear if the dhfr-51, -59, 
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and 108 mutations are present on the same allele or if there are three separate alleles each 
with one mutation.  
 To address this issue, Paul Wilson took three samples from the Rutshuru study with the 
following dhfr-51, -59, and -108 genotypes (which I determined by real-time PCR): 1. all 
mutant, 2. all wild-type, 3. mixed wild-type/mutant at each codon (146). These samples were 
subcloned and sequenced. For the wild-type sample, all of the 55 clones sequenced were 
wild-type. Similarly, all 90 clones from the mutant sample were mutant at dhfr-51, 59, 108. 
For the 33 cloned sequenced from the mixed sample, 9 were mutant and 24 were wild-type at 
dhfr-51, 59, 108. No single or double mutants (at codons 51, 59, 108) were observed. These 
results suggest that when there is a mutant genotype present at dhfr-51, 59, and 108, we can 
assume that the triple mutant haplotype is present. 
 One last complication of using real-time PCR for the genotyping of clinical samples is that 
these assays will only detect mutations at  dhfr-51, 59, 108 and dhps-436, 437, 540, 581, and 
613. In contrast, sequencing will pick up any alteration in these genes. Polymorphisms at 
other codons have been shown to be related to pyrimethamine resistance (such as dhfr codons 
16, 50, and 164), though these mutations are rare in Africa and are not the main determinants 
of pyrimethamine resistance (65). Other genetic modifications of dhfr have been noted in 
clinical samples. In fact, the subcloning of the thee Rutshuru samples found non-synonymous 
mutations at dhfr codons 19, 29, and 98. The role of these mutations in conferring resistance 
is unclear. In summary, the real-time PCR assays detect the major determinants of SP 
resistance. Other genetic alterations might be present, but most likely play a minor role in SP 
resistance. 
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Analysis  
For the purpose of the data analysis, the exposure was coded as the presence of the mutant 
genotype, even if it is not the major component of the sample.  
The main outcome of the analysis is any type of treatment failure by day 14. The presence 
of parasites on day 3 was investigated as a secondary outcome. (The presence of parasites on 
the third day after treatment is a sign of drug resistance). For the main analysis, children who 
died or were not assigned an outcome were not included. 
 To investigate the independent contributions of the dhfr and dhps mutations on treatment 
failure, linear risk regression was used. Interaction terms between mutations were evaluated 
using forward selection. Forward selection was used instead of backwards selection because 
the small sample size of this dataset limits the power to detect interactions.   
 To estimate the effect of dhfr and dhps mutations on treatment failure, linear risk 
regression was used. Covariates that were evaluated as potential effect modifiers and 
confounders were: hemoglobin, parasitemia, age, gender, clinic, treatment arm, and Z-score 
of weight for age. Effect modifiers were first evaluated by including an interaction term in 
the model and using the Wald test to determine if it was significantly contributing to the fit of 
the model. Interaction terms with p < 0.05 were retained in the model. All non-effect 
modifiers were then evaluated as potential confounders using the DAG (147). The same 
modeling technique was used to evaluate the effect of mutations on the presence of parasites 
on day 3. 
 To determine the impact of the loss to follow-up on the effect estimate of mutations on 
treatment failure, a simple sensitivity analysis was conducted. The effect estimates were re-
calculated under two scenarios: 1. All the excluded subjects were assumed to have failed 
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treatment and 2. All the excluded subjects were assumed to have not experienced treatment 
failure. 
IN VIVO EFFICACY STUDY IN PAILIN, CAMBODIA 
Collaborators  
This in vivo efficacy study was part of the monitoring program conducted by the 
Cambodian National Center for Parasitology, Entomology and Malaria Control (CNM) in 
collaboration with the World Health Organization (WHO) and the U.S. Naval Medical 
Research Unit No. 2 (NAMRU-2). Poravuth Yi (CNM), Denis Mey Bouth (WHO), Reiko 
Tsuyoka (WHO), Jason Maguire (NAMRU-2) and Chansuda Wongsrichanalai (NAMRU-2) 
were all involved in running this efficacy study. Pharath Lim, of the Pasteur Institute in 
Cambodia, genotyped the samples for msp1, msp2, and glurp. Thierry Fandeur and Federick 
Ariey at Pasteur supervised this work. Rithy Sem read the thin smear microscopy slides to 
determine the parasitemia, extracted the samples and genotyped 56 of the samples for pfmdr1 
mutations. Naman Shah developed the new pfmdr1 copy number assay and ran all samples 
for copy number determination. Alisa Alker genotyped 24 samples for pfmdr1 mutations, 
trained and supervised Rithy Sem and Naman Shah, carried out quality control on all 
laboratory work, and conducted the data analysis. Both Steve Meshnick and Chansuda 
Wongsrichanalai supervised the genotyping work and analysis. 
 
Clinical Study 
In 2004, an in vivo efficacy study was conducted in Pailin, Cambodia for surveillance of 
mefloquine-artesunate, which is the current first line treatment for uncomplicated malaria in 
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Cambodia. Between June and August 2004, 25 children and 56 adults were enrolled. The 
sample size was calculated in the same manner as described for the Rutshuru study. Briefly, 
with a 95% confidence interval and a precision of 10 percentage points,  20% loss to follow-
up and an expected prevalence of treatment failure of 20%, the required sample size is 73 
people (17, 148).  
The eligibility criteria for this study were 1. being older than 6 years, 2. having a slide-
confirmed P. falciparum infection (with no other species of Plasmodium present), 3. having 
an initial parasite density X 100,000 asexual parasites/Rl, 4. having a measured axillary 
temperature Y 37.5 ºC, 5. providing informed consent (by parent or guardian, when 
appropriate), and 8. willing to return for follow-up. Exclusion criteria included: 1. having a 
previous adverse reaction to mefloquine or artesunate, 2. having a severe chronic illness 
(such as HIV or kidney disease), 3. being pregnant, or 4. having signs of severe disease. The 
cutoff level of parasitemia in this study is lower than in the Rutshuru study because 
Cambodia is a low transmission area, where people have less immunity towards in malaria. 
As a result, the parasitemia threshold for severe disease is lower. 
 The parasitemia was first determined by thick smear microscopy, as previously described 
for the Rutshuru study. The thin smear slides were read after the study ended to confirm the 
parasitemia. However, the think smear slides revealed that 18 people (23%)  had a 
parasitemia greater than 100,000 parasites per Rl. These individuals were kept in the dataset 
because having a high parasitemia does not preclude the estimation of the effect of molecular 
markers on recrudescence. However, the inclusion of these subjects might make the results 
difficult to compare to other studies that followed the eligibility criteria more strictly.  
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At enrollment, a brief clinical exam was performed and a questionnaire was administrated. 
Approximately 2 ml of blood was taken and frozen. The subjects will be treated according to 
the national policy: they were initially given 1 dose of mefloquine (20 mg/kg) and 1 dose of 
artesunate (20 mg/kg). Additional doses of artesunate (10 mg/kg) were administered under 
observation at 24 and 48 hours. The patients stayed at the clinic for 3 days for observation. 
They also returned for follow-up visits at 7, 14, 21, 28, 35, and 42 days after the date of 
enrollment. Clinic staff actively sought out people who did not return for the follow-up visits.  
Nine adults and one child were eventually lost to follow-up, though all subjects were 
followed for at least two weeks. Out of the remaining 70 people, 24 people (34.3%) had a 
reoccurrence of P. falciparum parasitemia within 42 days of treatment. Half of these cases 
were classified as recrudescence, which results in a failure rate of 17.1%. The other half were 
classified as re-infections. The failure rate was substantially higher in children (43.8%) than 
in adults (11.9%).  
 
Study Population and Recruitment 
The Pailin referral hospital, where this study took place, serves the city of Pailin and 
also the surrounding rural areas. The clientele includes patients referred by medical 
clinics in the area and people who come to the clinic directly because they suspect they 
have malaria.  
The regular clientele at this clinic was invited to participate in this study. In addition, a 
staff member went to surrounding villages and asked if anyone had a fever. The staff 
member drove people with a fever to the clinic for evaluation. (Transportation in this area 
is very difficult and is a limiting factor in people seeking healthcare). 
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Collection of Clinical Covariates 
The study doctor administered a brief questionnaire, which contained questions on prior 
medical history, use of antimalarials in the last month, and basic sociodemographic 
information.  At each follow-up visit, the patient was screened for malaria (via thick smear 
microscopy), and the axial temperature was recorded. 
Parasite concentration was determined as previously described in section 2.4.4 with the 
following exception. At high parasitemia, counting the number of parasites relative to the 
number of RBC is more accurate than counting relative to the number of WBCs (C. 
Wongsrichanalai, per. com.). Therefore, when the parasitemia was determined to be greater 
than 10,000 parasites/µl using the WBC method, the counting was re-done in relation to 
RBCs. The number of parasites per 5,000 RBCs were counted and converted into the 
parasitemia by assuming there are 4,500,000 RBCs per µl. 
 
Biological Specimen Collection 
At enrollment, approximately 2 ml of peripheral blood was collected and frozen. 
Subsequent blood samples were taken after treatment and at any recurrent of parasitemia. 
These blood samples were collected from finger pricks and stored on 3M Whatman filter 
paper. 
 
Laboratory Procedures 
DNA extraction from whole blood and filter paper was performed using the Qiagen Qiamp 
DNA mini kit. All samples taken at enrollment and at reoccurrence of disease were 
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genotyped for pfmdr1 codons 86, 184, 1032, and 1042 using a real-time PCR assay based on 
MGB probes (58). These assays are very similar to those described for the dhfr and dhps
mutations in section 2.4.5. When compared to sequencing, these assays were all 100% 
sensitive and specific except for 184, whose sensitivity was 92% (58). However, this was 
based on a limited number of samples (n = 22). 
pfmdr1 copy number was assessed for all samples using a new assay. This assay consisted 
of combining in one reaction both the primers and a FAM-TAMRA probe specific to a 
conserved region of pfmdr1 and the primers and a VIC-TAMRA probe specific probe to -
tubulin. The primer and probes had been designed previously (99, 104). There exists only 
one copy of the -tubulin gene per genome. Therefore, by comparing the amount of pfmdr1 
relative to -tubulin, the pfmdr1 copy number can be assessed.  
In real-time PCR, quantification of DNA concentration is accomplished through the 
measurement of the cycle threshold (CT). The CT is the cycle at which the fluorescence rises 
above a threshold. Therefore, for each well, the CT was measured for both the -tubulin VIC 
dye and the pfmdr1 FAM dye 
pfmdr1 copy number was calculated according to the following formula: copy number = (1 
+ Ebtubulin)CT(btubulin) / (1 + Epfmdr1)CT(pfmdr1). The efficiency (E) of the b-tubulin was assumed to 
be 1. The efficiency of the pfmdr1 reaction was calculated for each plate by back-calculating 
the efficiency  from the formula above and a copy number of 1. DNA from the P. falciparum 
strain Dd2 was included on every plate as a control. Dd2 was previously determined to have 
4 pfmdr1 copies. In our assay, Dd2 had a mean copy number of 4.27 and a coefficient of 
variation of 5.77%. The end result is a continuous variable representing the average pfmdr1 
copy number for a particular sample.  
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Pharath Lim of the Pasteur Institute used paired samples taken at enrollment and 
reoccurrence of disease to classify the reoccurrence as either recrudescence (return of the 
original infection) or reinfection (a new infection). The number of variants in 3 polymorphic 
genes (msp1, msp2, and glurp) was determined using size fractionization in agarose gel 
electrophoresis, as described previously (124). If the second sample contained a sub-sample 
or the same variants as the first sample, the infection was classified as recrudescence. If the 
sample did not contain any of the original variants, then it was considered a re-infection. 
Analysis  
 The main outcome of the analysis was time to recrudescence. Since the subjects were 
assessed at distinct time points (1, 2, 3, 7, 14, 21, 28, 35, and 42 days), the actual time of 
recrudescence is interval censored. Subjects who were parasite-free on day 42 were 
considered treatment successes. Patients that were lost to follow-up, who developed a P. 
vivax infection, or who developed a P. falciparum infection that was determined to be a re-
infection were censored on the last day of disease-free follow-up.  
The secondary outcome assessed was time to parasite clearance. Parasite clearance time is 
the amount of time between treatment and the disappearance of P. falciparum asexual 
parasites from the peripheral blood.  
To determine the relationship between pfmdr1 haplotype and copy number and time to 
recrudescence, survival analysis was used. Discrete Cox proportional hazards model was 
used to take in account the interval censoring of the failure time. In Stata, discrete Cox 
proportional hazards model is estimated by a general linear model with the complementary 
log-log link (149). The different time periods are represented by indicator variables in the 
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model and the constant term is not included. The hazard ratio of the exposure is obtained by 
exponentiating the corresponding coefficient. The results of the discrete proportional hazards 
model was compared to the results obtained from a continuous Cox proportional hazards 
model using 3 different methods for the treatment of ties (efron, exact marginal likelihood, 
and exact partial likelihood). All variables were tested for the proportional hazards 
assumption. 
 The following covariates were evaluated as potential effect measure modifiers and 
confounders: previous antimalarial drug use, age, parasite density, hematocrit, and gender. 
These variables were coded to reflect their distribution and to maintain their relationship with 
treatment failure. Hazard ratio modification was determined by testing the interaction term 
between copy number and the covariate using the Wald test. If the p-value < 0.05, the 
covariate was considered an effect measure modifier. All non-modifiers were then evaluated 
in a directed acyclic diagram (DAG). This same modeling strategy was used to explore the 
relationship between genetic changes in pfmdr1 and parasite clearance time.  
To determine whether mefloquine-artesunate treatment selects for increased copy number 
and pfmdr1 haplotype, the genotype of the samples taken at enrollment and recurrence were 
compared. The Wilcoxon signed rank test (the non-parametric version of the paired t-test) 
was utilized to determine if the difference was statistically significant. 
 
CAMBODIAN CROSS-SECTIONAL STUDY 
Collaborators 
This study was conducted by Chansuda Wongsrichanalai of NAMRU-2 in collaboration 
with the Cambodian national malaria control program and the Pasteur Institute of Cambodia. 
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Rithy Sem read the microscope slides for parasite determination, genotyped all the samples 
for pfmdr1 haplotype and ran approximately 50 samples on the pfmdr1 copy number assay. 
Naman Shah ran the rest of the samples on the copy number assay. Alisa Alker conducted 
quality assurance on the laboratory work and completed all the data analysis. 
 
Study Design 
Clinical P. falciparum samples were collected between 2004-2005. The samples were 
taken before antimalarials were administered. The inclusion criteria included: symptomatic 
or asymptomatic P. falciparum malaria, being 18 years or older (changed to > 5 in 2005), and 
informed consent. Exclusion criteria included any contraindications to giving blood and 
severe disease. Basic clinical and demographic information were recorded. Samples were 
collected at malaria clinics in 5 towns: Pailin, Rattanakiri, Memut, Kampong Seila, and 
Chumkiri. A subset of samples taken at Pailin and Rattanakiri were from people enrolled in 
in vivo efficacy studies. The in vivo efficacy study in Pailin was described in section 2.5.2. 
The in vivo efficacy study in Rattanakiri was conducted using the same protocol but no one 
experienced a reoccurrence of parasitemia. The enrollment criteria for in vivo studies was 
more strict that the cross-sectional study: mixed species infections and asymptomatic disease 
were excluded in the in vivo but not the cross sectional study. In addition, children were 
eligible for the Pailin in vivo study.  
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Questionnaire and Clinical Assessment 
The study nurse administered a brief questionnaire, which contained questions on prior 
medical history, previous use of antimalarials, previous episodes of malaria, and basic 
sociodemographic information. Of note, the information on previous use of antimalarials and 
previous episodes of malaria are hard to interpret because they are based on self-report. In 
addition, fake antimalarials are common in Cambodia, which further decreases the reliability 
of this measure (150). Parasitemia was determined as described in section 2.5.4. 
Genotyping
Clinical samples were processed and genotyped as described in section 2.5.6. 
Analysis
The main purpose of this study was to describe the distribution of pfmdr1 haplotype and 
copy number in Cambodia. Therefore, the mean copy number and the prevalence of the 
different pfmdr1 haplotypes were calculated for each site.  
The secondary purpose of this analysis was to test whether pfmdr1 copy number varies by 
site. The assumptions of parametric statistics (normally distributed and homogeneity of 
variances) could not be met, even though numerous transformations of copy number were 
tried. Therefore, non-parametric statistics were used. The Kruskal-Wallis test was used to 
determine if copy number varied by site. To investigate whether copy number is related to 
any clinical characteristics (such a gender, parasite density, age, presence of mixed species, 
or the presence of gametocytes, either the Kruskal Wallis or the Spearman Correlation was 
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used. Lastly, to determine if copy number still varies by site when controlling for the clinical 
characteristics that are also related to copy number, a rank ANCOVA was used. 
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 Table 2.1 Comparison between the full cohort, the genotyped subjects, and the non-
genotyped subjects in Rutshuru, DRC 
Characteristic Genotyped Not genotyped p-value
# patients 212 37  
# men (%)  115 (55.0%) 14 (37.9%) 0.047 
median age in months (range) 25 (6-59) 23 (8-53) 0.304 
parasitemia (geo. mean) 38,249 23,849 0.049 
range of parasitemia (1043-454664) (1734, 280000)
mean hemoglobin 10 10.1 0.994 
mean temperature (ºC) 38.7 38.9 0.252 
Number excluded 17 0 1.000 
% Treatment failure 40.10% 21.60% 0.015 
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Figure 2.1  Map of Democratic Republic of Congo 
CHAPTER III: 
DHFR AND DHPS GENOTYPE AND IN VIVO RESISTANCE TO SULFADOXINE-
PYRIMETHAMINE IN CHILDREN WITH FALCIPARUM MALARIA IN THE 
DEMOCRATIC REPUBLIC OF THE CONGO 
by 
 
Alisa P. Alker, Walter M. Kazadi, Albert K. Kutelemeni, Peter B. Bloland, Antoinette K. 
Tshefu, and Steven R. Meshnick 
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ABSTRACT 
Malaria is endemic in the Democratic Republic of the Congo (DRC) and is a significant 
source of morbidity and mortality. Between June and September 2002, a therapeutic efficacy 
trial was conducted in four clinics in Rutshuru, Eastern DRC, comparing SP, amodiaquine 
and SP (AQSP), and artesunate and SP (ASSP) regimens for treating malaria in children. In 
the SP arm, 60.6% of the subjects experienced treatment failure after 14 days. The failure 
rate was lower in the combination arms (AQSP: 32%, ASSP: 21%). We genotyped 212 
samples from this study for mutations associated with SP resistance and investigated their 
association with treatment failure. The dhfr-108 and dhfr-51 mutations were nearly universal 
while 89% of the samples had at least one additional mutation at dhfr-59, dhps-437, or dhps-
540. The relationship between dhps mutations and treatment failure differed by initial 
parasite density: for children with a parasite density less than 45,000 parasites/µl, the risk of 
treatment failure was 37% for  children with mutations at  dhps-437 and dhps-540 mutation 
and 21% for children with neither mutation (risk difference (RD) = 17%, 95%CI: -4%, 36%; 
risk ratio (RR) = 1.9, 96%CI: 0.7, 5.7). In children with a parasite density greater than 45,000 
parasites/µl, the treatment failure risk was 59% and 8% for children with both mutations or 
neither mutation, respectively (RD = 51%, 95%CI: 34%, 67%; RR = 10.9, 95%CI: 2.8, 42.4). 
The high failure rate of SP from this and other studies, in addition to the high frequency of 
dhfr/dhps mutations, are indications that SP-based regimens are not an appropriate treatment 
for falciparum malaria in Eastern DRC.  
INTRODUCTION 
A major obstacle in the control of Plasmodium falciparum malaria is the development of 
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drug resistance. Drug resistance has increased malaria-related morbidity and mortality (151, 
152).  It has also amplified the cost of malaria control, as second line drugs and combination 
therapy are often more expensive. Sulfadoxine-pyrimethamine (SP) has been used widely in 
Sub-Saharan African for the treatment of uncomplicated malaria. However, resistance to SP 
has been documented in several Sub-Saharan countries (27, 34). As a result of the emergence 
and rapid spread of resistance to cheap antimalarial drugs, countries have been urged to shift 
to combination therapies. More over, SP is the only recommended drug for use for 
Intermittent Preventive Treatment in pregnant women (IPTp) for the time being. Therefore, 
monitoring of SP resistance is essential for determining whether or not an SP-based 
combination therapy regimen should be introduced as first line antimalarial drug for 
uncomplicated malaria or kept as an option for IPTp. 
SP resistance is conferred by mutations in the dihydrofolate reductase (dhfr) and 
dihydropteroate synthase (dhps) genes, which encode for the drugs’ targets. The dhfr-108-Ser 
mutation is the first to occur; subsequent mutations in dhfr and dhps incrementally add to the 
level of resistance (93). The presence of mutations at dhfr-51, dhfr-59, dhfr-108, dhps-437, 
and dhps-540 has been previously associated with SP treatment failure (77, 78, 80, 82, 86-
90). The role of mutations at dhps-436, dhps-581, and dhps-613 in treatment failure is less 
clear, as these mutations have received less attention due to their low prevalence in Africa.  
 Molecular markers of drug resistance, such as dhfr and dhps, can be used for surveillance 
of drug resistance (49, 93). For example, the prevalence of molecular markers of chloroquine 
resistance (pfcrt-76 and pfmdr1-86) and SP resistance were used assess drug efficacy in 
regions where in vivo efficacy studies were unfeasible (153, 154).  
 In the Democratic Republic of Congo (DRC), SP replaced chloroquine as the national first 
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line drug in 2001 as an interim strategy (131). However, SP has been in use in the Eastern 
region of the country since 1995 (P. Bloland, unpublished data). In vivo efficacy studies have 
shown that parasites in the East are more resistant to SP and chloroquine than the rest of the 
country (131). Methods to extend the current in vivo surveillance is greatly needed in DRC 
because of its large geographic size, limited health infrastructure, and political instability. We 
report here the prevalence of dhfr and dhps mutations in Eastern DRC and their relationship 
to 14 day risk of SP treatment failure in order to evaluate the use of these markers for 
surveillance of SP resistance. 
 
METHODS 
Study Design 
A therapeutic efficacy trial was conducted in Rutshuru, a district near the Rwandan border 
in Eastern DRC, to compare the efficacy of 3 regiments: 1. amodiaquine plus SP (AQSP); 2. 
artesunate plus SP (ASSP); and 3. SP alone (SP). The details of this study will be reported 
elsewhere. Briefly, this trial was a randomized, open label study following the WHO 1996 
protocol with the modifications suggested in the 2002 report (48, 131, 138). The study took 
place between June and September 2002 at four different clinics. Children were included in 
the study if they met the following criteria: 1. they were between the ages of 6 to 59 months; 
2. they did not suffer from severe malnutrition; 3. they had a P.  falciparum infection with no 
other Plasmodium species detected; 4. their parasitemia was between 2,000 to 200,000 
parasites / Rl; 5. there were no signs of severe disease; 6. the axillary temperature was equal 
or greater than 37.5 ºC; 7. there was no evidence of fever caused by illnesses other than 
malaria; 8. there was no history of allergic reactions to sulfa-containing drugs; 9. they were 
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able to return to clinic for follow-up visits; and 10. parent or guardian consent. 
249 children were initially enrolled and randomized to a treatment arm (AQSP: 75, ASSP: 
82, SP: 92).  All subjects received SP at enrollment (25 mg/kg sulfadoxine and 1.25 mg/kg 
pyrimethamine). Children in the combination arms received either amodiaquine (10 
mg/kg/day)  or artesunate (4 mg/kg/day) for 3 days. Follow-up visits occurred 1, 2, 3, 7, and 
14 days after enrollment, though the subjects were encouraged to return sooner if they were 
symptomatic. Subjects were excluded after enrollment if they did not return for scheduled 
visits, they reported using an antimalarial drug other than those given in the study, they 
developed another disease or their parent or guardian withdrew consent. 
 
Sample Processing and genotyping 
Approximately 50 Rl of blood was collected from 212 patients at enrollment. The blood 
was placed on IsoCode Stix filter paper (Schleicher & Schuell, Keene, N.H., USA), 
desiccated, and then transported to UNC Chapel Hill for processing. DNA was extracted 
according to the protocol included within IsoCode Stix’ packaging.  
All samples were genotyped at 3 dhfr (51, 59, 108) and 4 dhps (437, 540, 581, 613) 
codons using real-time PCR and MGB probes, as described previously (142). A subset of 
samples was genotyped for pfmdr1-86, pfmdr1-184, and for pfmdr1 copy number (58, 99). 
Genotyping of dhps-437 does not work in the presence of a mutation at dhps-436 (142). 
Therefore, all samples that were negative in the dhps-437 assay were amplified and 
sequenced, as previously described (142).  
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Analysis  
All statistical analyses were performed in Stata 8.2 (College Station, TX). The main 
outcome being investigated was 14 day treatment failure, as classified by the WHO protocol 
for in vivo efficacy studies in intense transmission areas (138). Early treatment failure is 
defined as having any of the following conditions: 1. development of severe malaria on days 
1-3; 2. parasitemia on day 2 higher than the parasitemia on day 0; 3. day 3 parasitemia that is 
greater than 25% of the day 0 parasitemia; or 4. presence of parasitemia on day 3 in the 
presence of fever (axillary temperature Y 37.5 °C). Late clinical failure is defined as either 1. 
development of severe malaria after day 3, or 2. presence of parasitemia on day 4-14 in the 
presence of fever (axillary temperature Y 37.5 °C). Late parasitological failure is defined as 
the presence of parasites on day 4-14 with an axillary temperature < 37.5 °C. If none of these 
criteria were met, the subject was considered to have an adequate clinical and parasitological 
response to treatment. In the statistical analyses, all types of treatment failure were combined. 
The main exposure of this analysis was the dhfr and dhps genotype. For each individual 
codon, a binary variable was created that reflected whether the mutant genotype was present. 
The following genotypes are considered mutant: dhfr-51-Ile dhfr-59-Arg, dhfr-108-Asn/Thr, 
dhps-437-Gly, dhps-540-Glu, dhps-581-Gly, dhps-613-Ser/Thr, pfmdr1-86-Tyr and pfmdr1-
184-Phe. 
For all analyses, risk differences were estimated using linear risk regression (general linear 
model with the identity link and a binomial error distribution). Linear risk regression is more 
appropriate than log risk or logistic regression in this study because risk differences more 
accurately reflect the magnitude of the effect when the outcome is common. In addition, 
linear risk regression is more appropriate for evaluating effect modification because it is on 
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the additive scale (155, 156). Risk differences have been used before in the evaluation of 
molecular markers on treatment failure in malaria (88). However, since most other studies 
use ratio measures of effect, RR will also be calculated to aid in the comparison to other 
studies. 
To evaluate the independent effect of each mutation on treatment failure, dhfr-59, dhps-
437, and dhps-540 were all included in the model a priori. Interactions between codons were 
then evaluated using a forward selection technique based on a p-value of 0.05. dhfr-108, 
dhfr-51, dhps-581, and dhps-613 were not included in this analysis because they are 
homogeneous in this population.  
Adjusted effects of these mutations were estimated by including confounders and effect 
measure modifiers in the linear risk model. Potential covariates included: initial parasite 
density (coded as a binary variable with a cut point at the median (45,000 parasites/Rl)), age 
(in years), hemoglobin (coded as a binary variable with the cut point at the mean (10)), fever, 
z-score of weight for age (coded as a binary variable with the cut point of –2), clinic, and 
treatment arm. Covariates were first evaluated as potential effect measure modifiers using 
forward selection. The interaction term was retained in the model and the covariate was 
considered an effect measure modifier when p X 0.05 in the Wald test. All non-effect 
measure modifiers were evaluated in a directed acyclic diagram to select a sufficient set of 
covariates that should be included in the model to control for confounding (147).  
Sensitivity analyses were performed to quantify the uncertainty caused by the 20 
exclusions (including the 3 deaths). The data were re-analyzed under the following scenarios: 
1. all the excluded patients failed treatment and 2. all the excluded patients did not fail 
treatment.  
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 The effect of dhfr and dhps mutations on the presence of parasites on day 3 was also 
investigated because parasite resistance can manifest clinically as delayed parasite clearance 
(65). The same modeling strategy was employed as described above.  
 
Ethics  
 The original study was reviewed by the Ministry of Health Technical Panel on behalf of 
the ethics committee. The Institutional Review Board at UNC Chapel Hill School of Public 
Health approved the genotyping and data analysis. 
RESULTS  
Efficacy study 
 The results of the entire cohort study will be presented elsewhere (W. Kazadi, unpublished 
data). For the 212 subjects that were genotyped, 17 patients were excluded, mostly due to 
loss to follow-up (AQSP: 3, ASSP: 1, SP: 13). In addition, three children died during the 
course of the study (AQSP: 0, ASSP: 1, SP: 2). The exact cause of death was not determined, 
though in one case a home remedy for malaria was suspected. In the remaining 192 subjects, 
the treatment failure was high (AQSP: 33%, ASSP: 24%, SP: 63%,). The majority of the 
treatment failures occurred after day 3 (late clinical failures & late parasitological failures), 
except for the SP arm in which 10 out of the 42 failures were classified as early treatment 
failures (Figure 3.1). The cause of treatment failure (i.e. recrudescence of the original 
infection or a new infection) was not assessed.  
For study participants whose samples were genotyped, the average age was 28.7 months 
(range: 6-59). The mean parasitemia at enrollment was 74,173 parasites per Rl (range: 1,043-
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454,664) while the mean hemoglobin was 10.0 gm/dl (range: 5.6-14.5 gm/dl). A quarter of 
the subjects were underweight (weight for age z-scores X -2 in reference to the NCHS/WHO 
international dataset (157)).  
 The genotyped sub-cohort (n = 212) was similar in these clinical characteristics to subjects 
to the subject that were not genotyped (n = 37, results not shown). However, the treatment 
failure rate was slightly higher in the genotyped subjects compared to the entire cohort 
(Entire cohort failure rate: AQSP: 32% ASSP: 22% SP: 61%). 
 
Genotyping 
 All genotyping was successful except for 10 samples for dhps-437. Sequencing revealed 
one sample contained 436-Ser 437-Gly, eight samples were 436-Ala 437-Ala, and one 
sample had a  436-Cys 437-Ala dhps genotype. The 436-Cys mutation, which is a two 
nucleotide difference from the wild-type sequence, has only been reported once before (71).  
 The prevalences of mutant and mixed (mutant and wild-type) genotypes in  dhfr, dhps, and 
pfmdr1 are presented in Figure 3.2. Most samples had a mutant dhfr-108 and dhfr-51 
component. Mutations at dhfr-59, dhps-437 and dhps-540 were very common (dhfr-59: 66%, 
dhps-437: 72% dhps-540: 67%). No mutation at dhps-613 was observed. Only one sample 
(1%) was wild-type at all dhfr and dhps codons while 92 samples (43%) contained the 
quintuple mutant (mutation at dhfr-108, -51, -59, dhps-437 and -540).  
 
Individual dhfr and dhps mutations and treatment failure 
 Since all patients received SP or an SP containing regimen, data on all patients were 
pooled. dhps-437 and –540 mutations were strongly associated with increased risk of 
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treatment failure (Table 3.1). Interestingly, the presence of both these mutations was 
associated with a slightly smaller increase in risk in treatment failure than with either of these 
mutations alone (interaction term between 437 and 540: 2 = 4.84, p=0.023). This suggests 
that these two mutations are antagonistic. dhfr-59 was only weakly associated with treatment 
failure. These results did not substantially change when only subjects in the SP arm were 
analyzed.  
 
dhps-437/540 mutations multivariable modeling of treatment failure 
 Because dhps-437 and dhps-540 had the biggest impact on treatment failure, they were 
evaluated further in multivariable modeling. The purpose of this analysis was to test for 
effect measure modifiers and to obtain an unconfounded estimate effect of dhps mutations on 
treatment failure. Information on the genotype of these two mutations was combined into a 
categorical variable with 3 levels: having neither mutation, having one mutation, and having 
both dhps-437 and –540 mutation. 
 In the effect measure modifier screening, initial parasite density was the only covariate 
identified (2 = 10.70, p=0.005). This result implies that the effect of dhps-437 and dhps-540 
differs by parasitemia. Of particular interest, neither treatment arm nor age were significant 
effect measure modifiers (treatment arm: 2 = 2.03, p=0.567; age: 2 = 0.12, p=0.940), which 
implies that the effect of the dhps mutations does not differ by regimen or by age.  
 In subjects with parasitemia less than 45,000 parasites/Rl, the dhps-437 and -540 mutations 
were associated with a small increase in risk of treatment failure compared to subjects with 
neither mutation (for one mutation: RD = 19%, 95%CI: 14%, 53%; for both mutations: RD = 
17%, 95%CI: -4%, 36%). The corresponding RR is 1.9 (95%CI: 0.7, 5.7) for one mutation 
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and 1.8 (95%CI: 0.8, 4.2) for both mutations. In subjects with parasitemia equal or greater 
than 45,000 parasites/Rl, the risk difference was 80% (95% CI: 54%, 105%) for one mutation 
and 51% (95%CI: 34% , 67%) for both mutations. The corresponding RR for one mutation is 
10.9 (95%CI: 2.8, 42.4) and  for both mutations is 7.3 (95%CI: 1.9, 28.2). The adjusted risk 
differences were similar to the crude estimates (Table 3.2). The sensitivity analysis revealed 
that the risk differences changed little by assuming either all the excluded children failed or 
were all successfully treated (Table 3.3).  
 
dhfr/dhps genotype and presence of parasites on day 3 
 The children with both dhps-437 and dhps-540 mutations were less likely to be 
parasitemic on day 3 compared to children without these mutations (31% versus 39%; RD= -
8, 95%CI: -23, 8). The corresponding relative risk is 0.8 (95%CI: 0.5, 1.2). The adjusted RD 
and RR were similar and magnitude and precision compared to the crude estimates (Table 
3.4). Thus, there was no association between dhps-437/540 mutations on the presence of 
parasites on day 3.  
DISCUSSION 
 In this study investigating the molecular determinants of SP treatment failure, mutations at 
dhps-437 and dhps-540 were strongly associated with treatment failure. However, this 
relationship differed by parasitemia level. In the low parasitemic group, subjects with either 
dhps-437/540 mutation had a 19% greater absolute risk of 14 day treatment failure than 
subjects with neither mutation. In contrast, among those with high parasitemia, the absolute 
risk of treatment failure was 80% greater in subjects with either dhps-437/540 mutation. 
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 The differential effect of genetic markers of resistance by parasitemia has been reported 
before: higher parasitemia was related to decreased ability to clear infections with pfcrt-76 
and pfmdr1-86 mutations after chloroquine treatment (63). High parasitemia is a sign of low 
partial immunity. Therefore, the larger effect of these mutations at high parasitmias might be 
caused by the inability of the immune system to clear resistant parasites. These results 
suggest that resistance might have a greater impact on severe disease. In addition, clinical 
information, such as parasite density, might need to be collected when monitoring for drug 
resistance in order for the prevalence of mutations to accurately depict the treatment failure 
rate. 
 Interestingly, the effect of dhps-437 and 540 did not vary by treatment arm, even though 
the different regimens had different failure rates. This suggests that dhfr and dhps mutations 
are important determinants of treatment failure, even when SP is used in combination. 
 In the evaluation of the independent effects of dhfr and dhps mutations, both dhps-437 and 
dhps-540 were strongly related to risk of treatment failure. dhfr-59 was only weakly 
associated. This is in contrast to a previous study that found these three mutations have 
similar independent effects (88). However, the effect of mutations has been shown to vary by 
region (76, 89), which is likely caused by variation in the prevalence of treatment failure, the 
presence of other dhfr/dhps mutations, and the prevalence of other risk factors for treatment 
failure across sites.   
 Despite the fact that delayed parasite clearance is a clinical manifestation of parasite 
resistance, we did not find an association between dhps-437/540 and the presence of parasites 
on day 3. In fact, an opposite trend was found. This finding is in contrast to a study in 
Columbia that found the presence of both dhfr-108 and dhfr-51 mutations was associated 
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with delayed parasite clearance (85). However, delayed parasite clearance was more common 
in Rutshuru, even in subjects without dhps-437 and -540 mutations. Therefore, other 
determinants of resistance might be masking the effects of these mutations.  
 The prevalence of dhfr and dhps mutations in Rutshuru is higher than previous reports 
from the Republic of Congo (132) but similar to Uganda (158). The high prevalence of the 
pfcrt-76 and pfmdr1-86 mutation in this cohort suggests these parasites are also resistant to 
chloroquine (159). The high prevalence of mutations associated with drug resistance 
confirms the presence of multi-drug resistant P. falciparum in this area. 
 While the mean pfmdr1 copy number in these samples was low (1.18), 14% of these 
samples contained greater than 1.5 copies. Increased pfmdr1 copy number has previously 
been associated with mefloquine and lumefantrine resistance (104, 107, 160) and has been 
seen in Africa before (100, 161). Therefore the use of lumefantrine and mefloquine in Africa 
should be implemented carefully to minimize the selection of resistant parasites, which are 
already present (though at low frequencies). 
The main strength of this study is analytical technique: effect measure modifiers were 
systematically screened, potential confounders were controlled for, and the uncertainty 
caused by exclusions was quantified. In addition, the genotyping of these samples by real-
time PCR assay has previously been validated: three samples whose genotype was 
determined by real-time PCR were cloned and sequenced to look for minor alleles. The 
genotype at dhfr-108, -59, and 51 from over 30 clones per sample was consistent with the 
real-time PCR genotyping of the entire sample (146). 
 The main limitation of this study is the limited follow-up. SP failures have occurred up to 
28 days after treatment (54) and therefore it is possible that some subjects failed after the 14-
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day follow-up ended. A recent review of in vivo efficacy studies found that, in general, the 
14-day follow-up period has limited sensitivity in detecting treatment failures (53). However, 
the 14-day follow-up had the best sensitivity (~80%) in areas of high resistance and high 
levels of transmission (Figures 3C and 4 in (53)). For example, Checchi et al. conducted an 
in vivo efficacy study with SP in Liberia in a high resistance, high transmission area(33). 
After 14 days, 33 (out of 68) people had experienced recurrent episodes. Between days 14 
and 28, 13 additional people experienced recurrent episodes. However, it was estimated that 
most of these were due to re-infection. After PCR correction, only 36 people total were 
considered to be true treatment failure. For this study, the sensitivity of the 14-day 
assessment in detecting treatment failure was 94%. Therefore, in the Rutshuru study, it is 
likely that most treatment failures were captured.   
 Another limitation to the interpretation of data is the lack of PCR correction to distinguish 
true recrudescence from re-infections However, the risk of re-infection is low during the first 
two weeks after treatment. Stephniewska et al. found that 73% of trials that conducted PCR 
genotyping before day 14 found that all instances of treatment failure were due to 
recrudescence .   
 Since outcome misclassification caused by the lack of PCR correction and the limited 
follow-up is nondifferential with respect to the exposure (dhfr/dhps genotype), these potential 
biases would likely bias the effect estimate towards the null (162). Another limitation of this 
study is that not all determinants of treatment failure were measured, such as drug 
pharmacokinetics, HIV status, and host genetic factors. 
 The high failure rates of SP and SP-combination therapy indicates that SP should no 
longer be used in this area. It was based on this and evidence from other sentinel site in DRC 
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that the country recently decided to shift from SP to the combination of amodiaquine plus 
artesunate (AQ+AS) as the new first line antimalarial. However, when a new regiment is 
introduced, dhfr and dhps could provide a complementary technique to efficacy trials to 
explore the geographic and temporal changes in resistance as far as SP is still used for IPTp. 
This study suggests that the collection of clinical information, such as parasite density, might 
be needed to use molecular markers for the monitoring of drug resistance. 
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Table 3.1 Risk differences and 95% confidence intervals for the independent effect of 
dhfr and dhps mutations on 14 day treatment failure in Rutshuru, DRC. The referent 
group for all comparisons is parasites with the wild-type genotype at dhfr-59, dhps-437, and 
dhps-540. RD = risk differences; CI = confidence interval. 
Mutation RD (%) CI (%) 
dhfr-59 9 -4, 22 
dhps-437 44 15, 73 
dhps-540 50 9, 91 
dhps-437 and -540 30 15, 45 
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Table 3.2 Risk differences and 95% confidence intervals for the association between 
dhps mutations and 14 day risk of treatment failure by parasitemia in Rutshuru, DRC. 
RD = risk differences; CI = confidence interval. 
mutation at Failed Total Risk Crude Adjusted†
Parasitemia dhps-437 + 540 (n) (n) (%) RD 95%CI RD 95%CI 
< 45,000 none 5 24 20.8 0.*  0.  
1 mutation 4 10 40.0 19 -15, 53 19 -14, 53 
 both mutations 25 67 37.3 17 -4 , 36 17 -3, 36 
 
Y 45,000 none 2 25 8.0 0.  0.  
 1 mutation 7 8 87.5 80 54, 105 85 71, 98 
 both mutations 34 58 58.6 51 34, 67 49 35, 64 
*Referent level 
†Adjusted for clinic, age, and z-score of weight for age 
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Table 3.3 Sensitivity analysis of the effect of dhps mutations on treatment failure by 
parasitemia in Rutshuru, DRC. Unadjusted risk differences (RD) and 95% confidence 
intervals (CI) were calculated. 
 
Scenario Parasitemia dhps-437/540 Risk (%) RD CI 
All excluded  < 45,000 none 24.0 0. * 
failed  treatment   1 mutation 40.0 16 -19, 51
both mutations 40.8 17 -3, 37 
 
Y 45,000 none 23.3 0.  
 1 mutation 90.0 67 43, 91 
 both mutations 63.6 40 21, 59 
 
All excluded were < 45,000 none 20.0 0.   
successfully treated 1 mutation 40.0 20 -14, 54
both mutations 35.2 15 -4, 34 
 
Y 45,000 none 6.7 0.  
 1 mutation 70.0 63 34, 93 
 both mutations 51.5 45 30, 60 
*referent level 
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Table 3.4 Risk differences and 95% confidence intervals for the association between 
dhps mutations and risk of day 3 parasitemia, Rutshuru, DRC. RD = risk differences; CI 
= confidence interval. 
Mutation at Parasitemic Total Risk Crude Adjusted†
dhps-437/540 on day 3 (n) (n) (%) RD CI RD CI 
none 20 52 38.5 0.*  0  
one 8 20 40.0 2 -24, 27 -2 -27, 23 
both 40 130 30.8 -8 -23, 8 -7 -22, 8 
*Referent level 
†adjusted for initial parasite density, age, clinic, and z-score weight for age
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Figure 3.1 Flowchart for the in vivo efficacy trial in Rutshuru, DRC. Clinical outcome 
was classified according to the WHO in vivo efficacy protocol for intense transmission areas 
(138). ACPR = adequate clinical and parasitological response.  
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Figure 3.2 Prevalence of mutant and mixed genotypes at codons associated with drug 
resistance.  The following genes were genotyped: dihydrofolate reductase (dhfr),
dihydropteroate synthase (dhps), chloroquine resistance transporter (pfcrt), and multidrug 
resistance gene-1 (pfmdr1). The pfcrt 76 genotype from these samples was previously 
reported (159). Sample size is 212 except for pfcrt (n=56) and pfmdr1 (n=58).  Black = 
mutant, gray = mixed.
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ABSTRACT 
Background. Artemisinin Combination Therapies (ACT) has recently been adopted as 
first-line therapy for Plasmodium falciparum infections in most malaria-endemic countries.  
One ACT, artesunate-mefloquine, has been used in Southeast Asia since 1994.  In this study, 
we determine whether artesunate-mefloquine failures are associated with genetic changes in 
the biomarker,  pfmdr1.
Methods. Blood samples were acquired from 80 patients enrolled in a 2004 in vivo 
efficacy study of artesunate-mefloquine in Pailin, Cambodia, and genotyped for pfmdr1 copy 
number and haplotype. 
Results. Having three or more copies of pfmdr1 was strongly associated with 
recrudescence (hazard ratio (HR) = 8.30, 95%CI: 2.60, 26.43). This relationship was 
maintained when controlling for initial parasite density and hematocrit (HR = 7.91, 95%CI: 
2.38, 26.29). Isolates from patients who had recurrent episodes after artesunate-mefloquine 
treatment had higher copy numbers than the paired enrollment sample (Wilcoxon Rank test, 
p = 0.040). 
Conclusion. pfmdr1 copy number was strongly associated with recrudescence to 
artesunate-mefloquine therapy. Treatment selected for parasites with increased pfmdr1 copy 
number.  pfmdr1 copy number should be evaluated further as a surveillance tool for 
artesunate-mefloquine resistance in Cambodia. 
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INTRODUCTION  
One of the challenges in the treatment and control of falciparum malaria is drug resistance. 
The Thai-Cambodian border, in particular, is a hotspot for the emergence of antimalarial 
resistance: some of the earliest reports of chloroquine and pyrimethamine resistance came 
from this area (23). In addition, high levels failure rates of mefloquine monotherapy were 
documented in the 1990’s (121).  
Artesmisinin combination therapy (ACT) has been promoted to be an effective strategy to 
combat the emergence and spread of resistance (163). Currently, 38 countries have adopted 
ACT as first-line regimens for the treatment of malaria (32).   However, a recent in vivo 
efficacy study on Thailand’s border with Cambodia reported a artesunate-mefloquine 28-day 
cure rate of 78.6% (39). In addition, an in vivo study on the Cambodian side of the border 
documented a 28-day cure rate of 86.7% in 2002 (164). These studies suggest declining 
susceptibility to the artesunate-mefloquine combination in this sub-region. However, it is not 
yet known whether these reported ACT failures are due to true parasite resistance, or other 
factors such as drug pharmacokinetics.  
Because antimalarial resistance can emerge quickly, surveillance is a key element to a 
successful malaria control program (18, 47). While the gold standard for monitoring drug 
efficacy is the in vivo trial, molecular markers could provide an inexpensive complementary 
tool. However, before they can be used, the relationship between specific molecular markers 
and in vivo resistance must be established.  
One possible molecular marker is Plasmodium falciparum multidrug resistance gene-1 
(pfmdr1).  Single nucleotide polymorphisms (SNPs) and gene copy number have previously 
been associated with in vitro resistance to a wide array of antimalarials, including 
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chloroquine, lumefantrine, quinine, halofantrine, mefloquine and artesunate (31, 97-99, 101, 
102, 107, 165). But in vitro and in vivo resistance are not always correlated (107). The 
purpose of this study was to determine whether pfmdr1 genetic changes are associated with 
in vivo evidence of resistance to artesunate-mefloquine in Cambodia.  
MATERIAL AND METHODS 
Clinical study     
As part of Cambodia’s National Malaria Control Program, 25 children and 56 adults with 
uncomplicated malaria were treated with artesunate and mefloquine between June and 
September, 2004.  The details of this study will be published elsewhere (148). Informed 
consent  was obtained from the subject or guardian. The WHO 2003 protocol for low 
transmission areas was followed (17). At enrollment, a brief clinical exam was performed 
and a questionnaire was administrated. 
Approximately 2 ml of venous blood was collected and frozen. Subjects were treated 
according to the national policy: they were given 25 mg/kg mefloquine and 12 mg/kg 
artesunate over 3 days. Subjects stayed at the clinic for 3-4 days (depending on when the 
parasites cleared) and had follow-up visits at 7, 14, 21, 28, 35, and 42 days after the date of 
enrollment. People who did not return on their own were actively sought out. In instances of 
reoccurrence of parasitemia, an additional blood sample was acquired and stored on 3M 
Whatman filter paper. 
 
Genotyping 
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DNA was extracted using the Qiamp DNA mini kit (Qiagen, Hilden, Germany). Samples 
taken at enrollment, day one, and recurrence of parasitemia were used to distinguish between 
recrudescence and reinfection. The number of variants in 3 polymorphic genes (msp1, msp2, 
and glurp) was determined using size fractionization (124). If the recurrence specimen 
contained one or more of the variants seen in the enrollment or day one specimen, the 
infection was classified as a recrudescence.  
Enrollment and recurrence samples were genotyped for pfmdr1 codons 86, 184, 1034, and 
1042 using real-time PCR. The protocol by Purfield et al. (58) was followed, except that the 
concentration of probes was changed to 200 nM.  
pfmdr1 copy number was assessed for all samples using a modification of two previous 
assays (99, 104). The primers and a FAM-TAMRA probe specific to a conserved region of 
pfmdr1 (from (99)) and the primers and a VIC-TAMRA probe specific to -tubulin (from 
(104)) were multiplexed so that both genes could be assayed in the same well. The primers 
were synthesized by MWG Biotech (High Point, NC) and the probes were synthesized by 
Applied Biosystems (ABI, Foster City, California). 
PCR reactions were performed on either the ABI Prism 7000 or ABI Prism 7300. Each 
reaction consisted of: pfmdr1 probe (150 nM), pfmdr1 primers (300 nM), -tubulin probe 
(100 nM), -tubulin primers (100 nM),  Abgene QPCR Matermix (1 x), DNA (2 Rl) and 
water up to 25 Rl. If amplification of a sample was unsuccessful (no amplification,  replicates 
being greater than 50% different, or a copy number < 0.6), it was repeated with 4 Rl DNA. 
The reaction conditions consisted of: 95°C for 15 minutes and then 50 cycles of 95°C for 15 
seconds and 60°C for one minute. The cycle threshold (CT) was calculated with the SDS 
software (ABI). DNA from strains 3D7 and Dd2 were included on each plate. The 3D7 DNA 
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was extracted from a laboratory grown culture and Dd2 DNA was acquired from MR4 
(MRA-387, ATCC Manassas Virginia). 
pfmdr1 copy number was calculated according to the following formula: copy number = 
(Etubulin)CT(tubulin) / (Epfmdr1)CT(pfmdr1). The efficiency (E) of  -tubulin, which was higher than 
that of pfmdr1, was assumed to be 2. Pfmdr1’s efficiency, relative to that of -tubulin, was 
calculated for each plate by assuming the 3D7 control has 1 pfmdr1 copy. Dd2, an additional 
control, was previously determined to have approximately 4 pfmdr1 copies (166, 167). In our 
assay, Dd2 had a mean copy number of 4.27 and a coefficient of variation of 5.77%.  
 
Statistical analysis 
The clinical data were entered into Excel (Microsoft) and analyzed with Stata 8.2 
(StataCorp, College Station, Texas). The clinical outcome of each patient was classified 
according to the WHO protocol (17). Since there were no early treatment failures,  the main 
outcome for this analysis was the recurrence of P. falciparum parasites in the peripheral 
blood. Recurrences of parasitemia were further categorized as reinfections or recrudescence 
by the msp1, msp2 and glurp genotyping.  
The copy number of samples taken before treatment and those taken at recurrence was 
compared using the Wilcoxon signed-rank test. 
The relationship between molecular changes in pfmdr1 and treatment failure was estimated 
using survival analysis. Since the subjects were assessed at distinct time points, the failure 
time is interval-censored. Discrete Cox proportional hazards model was used to take this 
censoring in account. This model was estimated using regression with a complementary log-
log link (149). Indicator variables representing four time periods (0-21, 22-28, 29-35, and 36-
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42 days) were included while a constant term was not estimated. All variables were assessed 
for the proportional hazard assumption. The main outcome was time to recrudescence. 
Subjects that were lost to follow-up were censored on their last visit. Subjects who developed 
a P. vivax infection or a P. falciparum re-infection were censored on the day of that second 
diagnosis. The precision of all hazard ratio estimates were evaluated by calculating the 
confidence limits ratio (CLR) (168). 
The genotype at codons 86, 184, 1034, and 1042 in pfmdr1 were combined into 
haplotypes, as previously described (99). Samples that were a mixture of haplotypes I and III 
were coded as haplotype III. The relationship between copy number and time to 
recrudescence was not linear on the log hazard scale. Therefore, copy number was coded as a 
binary variable of <3 copies and Y 3 copies to reflect the relationship between copy number 
and time to recrudescence and to meet the proportional hazards assumption of the model.   
The following covariates were evaluated as potential effect measure modifiers and 
confounders: previous use of antimalarials, initial parasite density, age, sex, and hematocrit. 
Initial parasite density was coded as a binary variable, with the cutoff point of 80,000 
parasites/µl. Effect measure modification was assessed with the Wald test for the interaction 
term in the model (p X 0.1 was considered significant). All non-effect measure modifiers 
were evaluated in a directed acyclic diagram to select a sufficient set of covariates to control 
for confounding (147). 
The population attributable rate fraction (AFp) and 95% confidence intervals were 
calculated according to (169). The specific formula for AFp was ((HRadj – 1)*p) / HRadj 
where HRadj = adjusted hazard ratio, and p = proportion of cases that were exposed.  
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 The relationship between molecular change in pfmdr1 and parasite clearance time was 
assessed using discrete Cox proportional hazards model in the same manner as described 
above. 
 
Ethics    
The pfmdr1 genotyping and data analysis were approved by the Institutional Review 
Boards at the U.S. Naval Medical Research Unit No. 2 and at UNC Chapel Hill School of 
Public Health. Both the genotyping and the efficacy study were approved by the National 
Ethics Committee of Cambodia. 
 
RESULTS 
Efficacy study    
Out of the 81 people enrolled, 10 were lost to follow-up, 7 were diagnosed with P. vivax,
and 25 people experienced late treatment failure between days 14-42 (Figure 4.1). msp1, 
msp2, and glurp genotyping determined that 13 out of the 25 recurrences were due to 
recrudescence of the original infection. In all the enrollment samples, there were 2 msp1 
variants, 5 msp2 variants, and 5 glurp variants. The prevalence of the most common 
msp1/msp2/glurp genotype was 8%.  
Enrollment samples were available for pfmdr1 genotyping for all but one subject. This 
subject was a child who recrudesced on day 14. Clinical and demographic information for the 
remaining 80 subjects are presented in Table 4.1.  
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Genotyping of enrollment samples 
Out of the 80 enrollment samples, 75 (93.8%) were successfully genotyped at all four 
pfmdr1 codons. Of the remaining five samples, genotyping of one sample was unsuccessful 
at pfmdr1-86, one was unsuccessful at pfmdr1-1034, and three were unsuccessful at pfmdr1-
1042. Most samples had either the I or III haplotype (Table 4.2). pfmdr1-86-Tyr was not 
observed.  
pfmdr1 copy number was successfully determined for all enrollment samples. The median 
copy number was 1.50 (range: 0.60 – 6.28) and 18.8% contained 3 or more copies. Elevated 
copy number was only observed in the presence of 86-Asn, 1034-Ser and 1042-Asn 
(haplotypes I and III). There was no association between copy number and pfmdr1-184 
genotype (ANOVA, F=0.51, p=0.479).  
 
Comparison of enrollment and recurrence pfmdr1 genotypes 
 pfmdr1 copy number was determined for all recrudescent (n=12) and all re-infection 
(n=12) samples. 75.0% (9/12) of the re-infection samples and 66.7% (8/12) of the 
recrudescent samples had a higher copy number than the corresponding enrollment sample. 
These differences were not statistically significant (Wilcoxon signed rank test, for 
recrudescent: z = 1.26, p = 0.209; for re-infection: z = 1.57, p = 0.117). However, when  
comparing all enrollment and recurrent samples, the difference was statistically significant 
(Wilcoxon signed rank test, z = 2.06, p = 0.040). Therefore, artesunate-mefloquine treatment 
appears to select for increased pfmdr1 copy number.  
Four recrudescent and 10 re-infection samples were genotyped for pfmdr1 polymorphisms. 
When comparing the haplotypes at enrollment and recurrence for the reinfection samples, 
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five were identical, one sample changed from haplotype IV to III, two samples changed from 
being mixed (haplotypes I and III) to haplotype III and two samples changed from having 
haplotype III to being mixed (haplotypes I and III). The four recrudescent samples had 
identical haplotypes to the enrollment sample (three of these paired samples had haplotype 
III and one had haplotype I).  Thus, there appears to be no selection of a particular pfmdr1 
haplotype due to artesunate-mefloquine treatment. 
 
pfmdr1 and time to recrudescence 
Subjects with increased pfmdr1 copy number recrudesced sooner and more often than 
subjects with low copy number (Figure 4.2 and Table 4.3). The crude hazard ratio for 
increased copy number (Y 3 copies compared to < 3 copies) was 8.30 (95%CI: 2.60, 26.43). 
Adjusting for confounders decreased the hazard ratio to 7.91 (95%CI: 2.38, 26.29). These 
results were not dependent on the statistical model, as the hazard ratio from a continuous Cox 
proportional model was similar in size and precision. Thus, pfmdr1 copy number is strongly 
related to time to recrudescence. 
For pfmdr1 haplotype, 11 out of 12 recrudescences occurred in subjects with haplotypes I 
and III. One subject with an incomplete haplotype also recrudesced. None of the four 
subjects with haplotype IV recrudesced, however the small sample size prevents further 
evaluation of this haplotype. The crude hazard ratio comparing haplotype III to I was 2.22 
(95% CI: 0.28, 17.34). Adjusting for confounders resulted in a slightly lower hazard ratio 
(1.88, 95%CI: 0.24, 15.00). There appears to be little difference between haplotype III and I, 
however the estimate is very imprecise (CLR = 61.36).   
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To investigate the impact of increased pfmdr1 on recrudescence in the entire cohort, the 
population attributable fraction was calculated. Using the prevalence of > 3 pfmdr1 copies in 
the cases  (58.3%) and the adjusted hazard ratio (7.91), the population attributable fraction of 
increased pfmdr1 copy number was 50.9% (95% CI: 4.1%, 74.9%). pfmdr1 copy number 
appears to contribute to the cause of half the cases of recrudescence observed in this study.  
When the outcome of all recurrences of parasites (recrudescence + reinfection) was used, 
the estimate of effect for copy number was lower (unadjusted HR = 4.51, 95%CI: 1.99, 
10.23; adjusted HR = 4.02, 95%CI: 1.73, 9.34). In contrast, the estimate for haplotype III was 
higher but very imprecise (unadjusted HR = 4.78, 95%CI: 0.64, 35.64; adjusted HR = 4.40, 
95%CI: 0.59, 33.02). Therefore, the estimated effect of pfmdr1 haplotype but not copy 
number changes depending on whether the treatment failures were PCR corrected. This 
suggests that if some misclassification of recrudescence and reinfection had occurred, the 
interpretation of the effects would not be substantially different.  
pfmdr1 copy number is a potential screening tool for drug resistance. Greater than 3 copies 
identified cases of recrudescence with a  sensitivity and specificity of 58.3% and 88.2%, 
respectively, and a positive predictive value of 66.7%. Including information on either 
pfmdr1 haplotype or initial parasite density increased the specificity but decreased the 
sensitivity (Y 3 copies + haplotype III: sensitivity = 50.0%, specificity = 91.2%; Y 3 copies + 
parasitemia Y80,000: sensitivity = 50.0%, specificity = 91.2%).  
 
pfmdr1 and parasite clearance time 
Out of the 80 subjects, 4 (5.0%) cleared the parasitemia by day 1, 41 (51.3%) cleared by 
day 2, and 27 (33.8%) cleared by day 3, and 8 (10.0%) cleared by day 4. The parasite 
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clearance times observed in this study are longer than reported previously for artesunate-
mefloquine (170).   
Increased copy number was not associated with delayed parasite clearance when 
controlling for parasite density and hematocrit (Table 4.4). There was a small association 
between pfmdr1 haplotype and delayed parasite clearance time, though the estimate was 
imprecise. 
 
DISCUSSION  
In this study, pfmdr1 copy number was strongly associated with recrudescence after 
treatment with artesunate-mefloquine. After adjusting for confounding, subjects with greater 
than 3 copies of pfmdr1 had 7.91 times the risk of recrudescence as subjects with less than 3 
copies. pfmdr1 copy number was an important determinant of recrudescence, as 
demonstrated by the population attributable fraction of 50.9%. In addition, artesunate-
mefloquine treatment was found to select for increased pfmdr1 copy number, since parasites 
from recurrent infections had significantly higher copy numbers than parasites from those 
same patients on enrollment.  These data demonstrate that artesunate-mefloquine failures are 
associated with a specific drug-resistance biomarker, and that treatment may increase the 
prevalence of this biomarker in the general population. 
Our observed association between pfmdr1 and failure is consistent with previous in vivo 
studies that looked at mefloquine monotherapy (107) and artesunate-mefloquine combination 
therapy (104).  In both studies, associations between pfmdr1 copy number and drug failure 
were found, but no association was seen between pfmdr1 haplotype and drug failure.  In 
contrast, numerous in vitro studies have found associations between both copy number and 
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haplotype and in vitro IC50  (104-107, 114). There are 3 possible reasons for this.  First, the 
effect of these mutations might be too small to be seen in vivo. Second, determinations of 
SNPs in complex polyclonal infections could result in misclassification. Third, in Pailin, the 
pfmdr1 genotype had minimal variation, with some sensitive genotypes being either rare or 
absent, so the effect might have been missed.  
It has been suggested that increased pfmdr1 copy number might cause artesunate and 
mefloquine resistance (98, 99, 107, 165, 171). The observed drug failures are probably due to 
mefloquine resistance, since a study in Pailin in 2001-2002 found the clinical isolates had 
high mefloquine IC50’s and low artesunate IC50’s (119). Also, parasite clearance is 
predominantly due to artesunate, and no effect of pfmdr1 copy number on parasite clearance 
time was observed in this study.  Therefore, the effect pfmdr1 copy number on recrudescence 
is most likely due to the effect of pfmdr1 on mefloquine sensitivity, not artesunate sensitivity 
[21]. 
This is the first  observation of an increase in pfmdr1 copy number in parasites isolated 
after artesunate-mefloquine treatment.  Since mefloquine has a much longer half-life than 
artesunate (10-14 days versus 1 hour) (172, 173), resistant parasites were probably selected 
by exposure to subtherapeutic concentrations of the single drug, mefloquine (174). Selection 
for mefloquine resistance in Pailin may have also been facilitated by  the pre-existence of 
resistance to this drug (123, 175). This observation suggests that ACT selects for resistance 
to the non-artemisinin partner drug.  
Strengths of this study include the fact that genotyping was done directly on peripheral 
blood samples, which negates the potential bias caused by culturing (58). Another strength is 
its 42-day follow-up with PCR correction (53).  The main limitation of this study is the small 
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sample size, which affected the power and the precision of the effect estimates, especially for 
pfmdr1 haplotypes.  Another limitation is that not all predictors of recrudescence were 
measured, such as pharmacokinetics, host genetics, immunity and nutritional status.  
Molecular markers of drug-resistant malaria, such as pfmdr1, are promising tools for the 
surveillance of drug resistance.  pfmdr1 copy number is not only strongly associated with 
recrudescence to artesunate-mefloquine but also with Coartem failure (artemether-
lumefantrine) (176). Surveillance for increased pfmdr1 copy number could aid malaria 
control efforts by pinpointing areas where these drugs may be failing. 
 
86
Table 4.1 Clinical characteristics of the subjects in the Pailin in vivo efficacy study that 
were genotyped for pfmdr1. Sample size is 80, unless otherwise specified. 
Characteristic  Number 
men (%) 57 (71.3%) 
median age (range) 20 (6 - 65) 
geo. mean parasitemia* (SD†) 18887.7 (116410) 
mean hematocrit (SD) 38.7 (5.3) 
previous use of antimalarials‡ (%) 28 (37.8%) 
*parasites / µl
†standard deviation 
‡in the past month by self-report, n=74 
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Table 4.2 pfmdr1 haplotypes of samples taken at enrollment with successful genotyping 
at all codons. Amino acids representing the mutant genotype are in bold. 
86 184 1034 1042 Haplotype* Number
Asn Tyr Ser Asn I 13 
Asn Phe Ser Asn III 57†
Asn Phe Ser Asp IV 4‡
Asn Tyr Cys Asn V 1
*from (99) 
†5 samples were mixed at 184 
‡1 sample was mixed at 1042 
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Table 4.3 Hazard ratios and 95% confidence intervals for time to recrudescence by 
pfmdr1 copy number and haplotype. HR = hazard ratio and CI = confidence interval. 
 No. No. Crude Hazard Ratio Adj† Hazard Ratio
Level Subjects Recrudesced HR CI CLR* HR CI CLR
Copy 
number < 3 65 5 1. ‡ 1.   
Y 3 15 7 8.30 2.60, 26.43 10.17 7.91 2.38, 26.29 11.04
pfmdr1 I 12 1 1.   1.   
haplotype III 47 10 2.22 0.28, 17.34 61.93 1.88 0.24, 15.00 62.50
Hematocrit < 40 39 7 1.
Y 40 41 5 0.68 0.22, 2.15 9.8 
Parasite < 80,000 58 6 1.   
density Y 80,000 22 6 3.09 1.00, 9.61 9.61
*confidence limit ratio = upper limit / lower limit 
†adjusted for initial parasite density and hematocrit 
‡referent level 
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Table 4.4 Hazard ratios and 95% confidence intervals for the relationship between 
parasite clearance time and pfmdr1 copy number and haplotype. HR = hazard ratio, CI = 
confidence interval and PCT = parasite clearance time. 
 
Median Crude Hazard Ratio Adj† Hazard Ratio
Level 
 PCT 
(hours) HR CI CLR* HR CI CLR 
Copy 
number < 3 48 1. ‡ 1.
Y 3 72 0.65 0.34, 1.24 3.65 0.98 0.48, 1.98 4.13 
 
pfmdr1 I 48 1. 1
haplotype III 48 0.81 0.40, 1.63 4.08 0.83 0.41, 1.69 4.12 
 
Hematocrit < 40 48 1.      
 Y 40 48 1.23 0.76, 2.00 2.63    
 
Parasite < 80,000 48 1.      
density Y 80,000 72 0.26 0.14, 0.49 3.50       
*confidence limit ratio (CLR) = upper limit / lower limit 
†adjusted for initial parasite density and hematocrit 
‡referent level 
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Figure 4.1 Flowchart describing the results of the in vivo efficacy trial in 2004 in Pailin, 
Cambodia.  
Mefloquine + artesunate
given at enrollment
n = 81
Lost to follow-up
n = 10
P. vivax infection
n = 7
No recurrence 
of parasitemia
n = 39
Recrudescence
n = 13
Reinfection
n = 12
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Figure 4.2 The percentage of subjects who have not recrudesced over time after 
mefloquine + artesunate treatment in Pailin, Cambodia. Copy number was rounded to the 
nearest integer. Only samples with haplotypes I, III, and IV were included. The haplotypes 
are defined in Table 4.2.  
A. pfmdr1 copy number                     B. pfmdr1 haplotype 
CHAPTER V: 
GEOGRAPHIC DISTRIBUTION OF PFMDR1 MUTATIONS AND COPY NUMBER 
IN PLASMODIUM FALCIPARUM IN CAMBODIA 
by 
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ABSTRACT 
Plasmodium falciparum malaria is endemic in Cambodia. Because of widespread multi-
drug resistant malaria in the region, the national first-line treatment was changed to 
mefloquine-artesunate in 2001. pfmdr1 single nucleotide polymorphisms (SNPs) and 
increased copy number have been associated with mefloquine resistance. To determine the 
geographic distribution of these genetic changes, we genotyped 457 clinical samples for 
pfmdr1 copy number and 255 samples for pfmdr1 SNPs from 5 geographically disparate 
clinics. Most samples had the following pfmdr1 genotype: 86-Asn, 1034-Ser, 1042-Asn. 
There was more variability at codon 184. pfmdr1-184-Phe was more common near the Thai-
Cambodian border than in Eastern Cambodia. pfmdr1 copy number also varied 
geographically. In addition to Pailin near the Thai border, Chumkiri in Central Cambodia 
also had a high mean pfmdr1 copy number, which suggests mefloquine resistance is more 
widespread than previously thought.  
INTRODUCTION  
Plasmodium falciparum causes over 500 million clinical cases of malaria each year, most 
of which are in developing countries (3). One of the major obstacles in controlling this 
disease is drug resistance. Drug resistance evolves more quickly in areas of low transmission, 
such as in Asia and South America. In fact, sulfadoxine-pyrimethamine resistance in Africa 
appears to have arose from the importation of parasites from Southeast Asia (28). Therefore, 
even though the majority of the malaria burden is in Africa, the control of drug resistance in 
Asia is essential for malaria endemic countries worldwide.  
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The Thai-Cambodian border region is a hotspot for the emergence of drug resistance in 
Asia. One of the first reports of chloroquine resistance in P. falciparum came from this area 
in 1961 (23). Since then, these parasites have developed high levels of resistance to 
chloroquine and SP, making this region one of the most drug resistant areas in the world (27, 
177). Mefloquine was first used in this region in combination with SP in the 1980s and later 
as monotherapy in the 1990s (25). High levels of mefloquine resistance was documented in 
the 1990’s (38, 123). As a result, mefloquine-artesunate replaced mefloquine monotherapy in 
1995 on the Thai side of the border and in 2001 on the Cambodian side of the border.  Recent 
clinical studies indicate the efficacy of the mefloquine-artesunate combination is decreasing 
at the Thai-Cambodian border ((39) and Mey Bouth et al. in review). The decreasing efficacy 
of mefloquine-artesunate is most likely due to mefloquine resistance, as clinical samples 
taken from Pailin were resistant to mefloquine but sensitive to artesunate in in vitro assays 
(119). 
In contrast to the situation at the Thai border, P. falciparum in Eastern Cambodia remains 
sensitive to both mefloquine and chloroquine (38). The level of resistance in Central 
Cambodia appears to be variable, though only a few in vivo efficacy studies have been 
conducted in this area (38). The increasing mefloquine-artesunate treatment failure and the 
geographic variation in resistance suggest expanded surveillance is greatly needed in 
Cambodia. 
One method to extend surveillance of drug resistance beyond sentinel sites is to measure 
molecular markers of drug resistance. In particular, detecting genetic changes in the 
Plasmodium falciparum multi-drug resistance gene-1 (pfmdr1) might be a useful measure 
because it has been associated with resistance to a wide array of antimalarials. pfmdr1 copy 
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number has been associated with increased in vitro resistance to mefloquine, lumefantrine, 
and quinine, and decreased sensitivity to artesunate (98, 99, 101, 178-180). In addition, 
increased pfmdr1 copy number predicts in vivo treatment failure to mefloquine and 
mefloquine-artesunate combination therapy (104, 107, 181). Yet increased pfmdr1 copy 
number is not associated with increased chloroquine resistance. In fact, some studies suggest 
the opposite trend (99, 178).  
Single nucleotide polymorphisms (SNPs) at codons 86, 184, 1034, 1042, and 1246 in 
pfmdr1 have been related to in vitro resistance to mefloquine, chloroquine, lumefantrine, 
artesunate, and quinine (97-99, 101, 102, 182). pfmdr1-86 has been associated with clinical 
outcome after chloroquine treatment (though it is not the main determinant of chloroquine 
resistance) (64, 183). No association has been demonstrated between pfmdr1 haplotype and 
mefloquine treatment failure (104-107).   
The purpose of this study was to determine the geographic distribution of pfmdr1 SNPs 
and copy number at 5 distinct sites in Cambodia in order to explore the usefulness of pfmdr1 
as a method for drug resistance surveillance.  
 
METHODS 
Clinical study  
Clinical samples of Plasmodium falciparum were acquired from five sites in Cambodia 
(Pailin, Memut, Kg. Seila, Rattanakiri, and Chumkiri) between 2004-2005 (Figure 5.1). 
Eligibility criteria included: having uncomplicated falciparum malaria, being 18 years or 
older (changed to 5+ years in 2005), having no contraindications to giving blood and 
providing informed consent. At Pailin and Rattanakiri, samples from on going in vivo 
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efficacy studies were also included (Mey Bouth et al in review, chapter 4 in this dissertation). 
These studies had slightly different eligibility criteria (mixed Plasmodium species infections 
were excluded and the Pailin efficacy study included children older than 5 years old). In the 
Pailin in vivo study, mefloquine-artesunate had an 88.5% 42-day failure rate (when PCR 
corrected for reinfections). The in vivo study at Rattanakiri had a 100% cure rate after 28 
days.  
A drop of peripheral blood was collected to make thick and thin smear slides. The thick 
smear slide was used to assess eligibility criteria. The slides were transported to Phnom Penh 
where trained microscopists used the thin smear slides to measure the parasite density, 
gametocyte density, and the presence of non-falciparum species.  
A questionnaire was administered to all subjects, which collected information on 
demographics and past medical history. Approximately 2 Rl of blood was collected, frozen, 
and transported to Phnom Penh for processing. All subjects were treated according to the 
national policy (25 mg/kg mefloquine and 12 mg/kg artesunate over 3 days).  
 The pfmdr1 genotyping and data analysis were approved by the Institutional Review 
Boards at the U.S. Naval Medical Research Unit No. 2 (NAMRU-2) and at UNC Chapel Hill 
School of Public Health. The National Ethics Committee of Cambodia approved both the 
genotyping and the in vivo efficacy studies. 
 
Genotyping 
 All frozen blood samples were extracted using the Qiamp DNA extraction kit. pfmdr1 
copy number was determined for all samples, as previously described (181). In addition, a 
subset of samples were genotyped for pfmdr1 codons 86, 184, 1034, and 1042 at Pailin, 
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Rattanakiri, Memut, and Kg. Seila, as previously described (58, 181). (The Chumkiri samples 
have not yet been genotyped for mutations in pfmdr1). The samples were not genotyped at 
pfmdr1-1246 because previous surveys of Cambodia and Thailand did not find this mutation 
(31, 98, 184). 
Analysis 
 The main questions being addressed in the analysis were: if genetic changes in pfmdr1 
vary by site and whether any clinical characteristics of the subset are associated with these 
genetic changes in the parasite. pfmdr1 copy number is not normally distributed and the site 
by site variances were heterogeneous. Multiple transformations of copy number were tried, 
yet none allowed pfmdr1 copy number to be normally distributed and have homogenous 
variances. Therefore, non-parametric statistical tests were employed, which do not rely on 
these assumptions.  
Kruskal-Wallis and Spearman Correlations were used to determine if pfmdr1 copy number 
varies by site and by clinical characteristics. A rank ANCOVA was used to test if copy 
number varied by site when controlling for clinical characteristics. To assess whether 
pfmdr1-184 genotype varies by site and by clinical characteristics, logistic regression was 
used. Statistical analyses were conducted in Stata 8.2 (StataCorp, College Station, Texas) 
except for the rank ANCOVA test, which was carried out in SAS 9.13 (SAS Institute, Cary, 
North Carolina).  
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RESULTS 
 In total, blood samples were collected from 457 subjects with uncomplicated falciparum 
malaria between 2004-2005. The clinical characteristics of the subjects are presented in 
Table 5.1. The distribution of age, gender, parasitemia, and prevalence of mixed infections 
varied by site. In particular, Chumkiri had the highest geometric mean parasitemia, the 
highest prevalence of mixed species and the lowest proportion of women. 
 pfmdr1 copy number was successfully determined for 434 out of 457 samples (success 
rate: 95%). pfmdr1 copy number ranged from 0.60 to 6.28. 16.6% of the samples had 2 or 
more copies. 
 Out of 255 samples ran in the pfmdr1 allelic discrimination assays, 238 samples were 
successful at all four codons and 10 samples were successfully genotyped in at least one 
codon. There was little variation in genotype at codons 86, 1034 and 1042. Most samples had 
the genotype 86-Asn 1034-Ser 1042-Asn (Table 5.2).  
Samples with 2 or greater pfmdr1 copies all had the following genotype: 86-Asn 1034-Ser 
and 1042-Asn but they varied in 184 genotype. There was no relation between increased 
copy number (defined as having 2 or more copies) and pfmdr1-184 genotype when 
controlling for site (logistic regression, OR = 1.09, 95%CI: 0.40, 2.98).  
pfmdr1 copy number varied substantially by site (Kruskal-Wallis test, 2 = 100.98, p < 
0.001). Higher copy numbers were seen in Pailin and Chumkiri compared to K. Seila, 
Memut, and Rattanakiri (Figure 5.2). The variance of copy number also differed by site: the 
sites with the highest copy number also had the highest variation in copy number (Levene’s 
test of homogeneity, W = 54.39, p < 0.0001).   
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pfmdr1 copy number was higher in men and in mixed species infections (Table 5.3). In 
addition, parasite density was positively associated with  pfmdr1 copy number. When gender, 
mixed infections and parasite density was controlled for, site was still a significant predictor 
of pfmdr1 copy number (rank ANCOVA, Chi-square = 59.21, df = 4, p < 0.0001).  
The prevalence of pfmdr1-184-Phe also varied significantly by site (Chi-square = 71.59, df 
= 3, p < 0.0001). 184-Phe was more common in West (Pailin) than in the East (Rattanakiri) 
(Figure 5.3). Age, parasitemia, gender, presence of gametocytes, mixed infection were not 
related to pfmdr1-184 genotype  
 
DISCUSSION  
In this cross-sectional study at five different sites in Cambodia, we found substantial 
heterogeneity in pfmdr1 copy number. Pailin (near the Thai border) and Chumkiri (in central 
Cambodia) both had high pfmdr1 copy number while Memut (in central Cambodia) and 
Rattanakiri (near the Vietnam border) had relatively low pfmdr1 copy number. There was 
very little variation in the genotype at pfmdr1 codons 86, 1034 and 1042. However, the 
prevalence of pfmdr1-184-Phe decreased from West to East. 
Previous in vivo and in vitro studies have demonstrated an increasing level of mefloquine 
resistance near the Thai border while the Eastern part of the country has remained relatively 
mefloquine sensitive (38, 119). Surveillance for drug resistance has been limited to 8 sites 
throughout Cambodia, most of which are near the international borders. However, the 
increased pfmdr1 copy number at Chumkiri, which is in the middle of the country, 
demonstrates that the geographic distribution of drug resistance is more complex than 
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previously thought. Further investigation of the level of mefloquine resistance, either through 
in vivo or in vitro methods, should be employed in Chumkiri to confirm this finding.  
In contrast to pfmdr1 copy number, pfmdr1 haplotype varied little across the five clinics. 
Most of the samples had the following pfmdr1 haplotype: 86-Asn 1034-Ser and 1042-Asn, 
though there was substantial variation at pfmdr1-184. A previous Cambodian study found 
similar prevalences of 86-Asn, 1034-Ser, and 184-Phe genotypes, but they found that 18% of 
the samples contained 1042-Asp. In contrast, in this currently study, 1042-Asp was only 
found in 5.4% of the samples. This inconsistency is probably due to the limited sample size 
of the previous study and slight differences in the geographic origin of the samples. 
The presence of the pfmdr1-184 mutation increased from West to East. The reason for this 
trend is unclear because the role of the pfmdr1-184 genotype on mefloquine and chloroquine 
resistance is ambiguous. Khim et al. demonstrate that the presence of the pfmdr1-184 
mutation is associated with mefloquine resistance (31). However, most studies found no 
relation between 184 and either mefloquine or chloroquine resistance (98, 99, 104, 107, 112, 
182, 185, 186). It is possible that the East-West trend of pfmdr1-184 is due to increasing 
selective pressure by mefloquine or chloroquine. This trend is more likely due to pfmdr1-184 
being in disequilibrium with an allele that is affected by drug pressure. 
This is the first report of an association between pfmdr1 copy number and clinical 
characteristics (gender, age, parasite density, and the presence of a non-falciparum 
Plasmodium species). The presence of dhfr and dhps mutations has been associated with age 
in African children (187). The reason for the increased copy number in mixed species 
infections is unclear, though might be related to the decreased number of P. falciparum 
clones in the sample (due to competition with the other Plasmodium species). 
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This study demonstrates the utility of molecular markers for surveillance of drug 
resistance. A large number of samples can be processed in a relatively short amount of time. 
In addition, surveillance can be expanded beyond sentinel sites. The main weakness of this 
project is that treatment outcome was not determined for most of the participants. Therefore, 
we cannot determine if the relationship between genetic changes in pfmdr1 and treatment 
failure varies by region. Another limitation of this study is the limited sample size, especially 
at Kg. Seila. Nonetheless, measuring pfmdr1 copy number should be evaluated further as a 
technique to complement the current in vivo efficacy monitoring in Cambodia and in other 
regions where quinoline compounds are being used. 
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Table 5.1 Clinical characteristics of study participants at 5 clinics in Cambodia 
 
Pailin Kg. Seila Chumkiri Memut Rattanakiri
Total, N (%) 112 (24.5) 11 (2.4) 78 (17.1) 174 (38.1) 82 (17.9) 
Female, N (%) 35 (31.2) 2 (18.2) 12 (15.4) 63 (36.2) 31 (37.8) 
Age,  
mean (range) 25.1 (6-65) 23.7 (18-40) 27.8 (16-57) 30.0 (18-63) 27.7 (18-60)
Parasitemia, 
geometric mean 14123 4975 24907 17125 5443 
Parasitemia > 
50,000*, N (%) 37 (33.0) 4 (36.4) 30 (47.6) 68 (39.8) 13 (15.9) 
Gametocytemia, 
N (%) 4 (4.6) 1 (9.1) 4 (5.1) 11 (6.3) 1 (1.3) 
Mixed infection, 
N (%) 6 (6.8) 1 (9.1) 46 (59.0) 5 (2.9) 4 (5.1) 
*parasites / Rl
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Table 5.2 pfmdr1 haplotype and mefloquine phenotype at Pailin, Kg. Seila, Memut, and 
Rattanakiri. Only samples with complete haplotype are included in this table. The sample 
size at each site is: 106 at Pailin, 9 at Kg. Seila, 73 at Memut, and 50 at Rattanakiri.  
 
in vitro 
MQ  Frequency (%)
Haplotype* 86† 184 1034 1042 phenotype‡ Pailin Kg. Seila Memut Rattanakiri
I Asn Tyr Ser Asn R/S 19.8 88.9 78.8 89.8 
II Tyr Tyr Ser Asn S 0 0 1.5 6.1 
III Asn Phe Ser Asn R 75.00 11.1 12.1 4.1 
IV Asn Phe Cys Asp S 0 0 1.5 0
IV Asn Phe Cys Asn S 3.1 0 6.1 0 
IV Asn Phe Ser Asp R/S 1.0 0 0 0 
V Asn Tyr Cys Asn ? 1.0 0 0 0 
*Haplotype based on categorization from (99) 
†Amino acids in bold represent the mutant genotype 
‡ From (31, 99). MQ = mefloquine, R = resistant and S = sensitive. R/S indicates the studies 
had contrasting results. 
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Table 5.3 Clinical and demographic factors and their relationship with pfmdr1 copy 
number 
Chi-square/  
Covariate Test Spearman's Rho p-value 
Site Kruskal-Wallis 100.98 < 0.001 
in vivo efficacy participant Kruskal-Wallis 3.57 0.059 
Presence of gametocytes Kruskal-Wallis 0.353 0.552 
Presence of non-falciparum 
Plasmodium species Kruskal-Wallis 23.91 < 0.001 
Parasite density 
Spearman 
Correlation 0.116 0.018 
Age 
Spearman 
Correlation 0.088 0.070 
Gender Kruskal-Wallis 5.277 0.022 
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Figure 5.1 Map of Cambodia showing the 5 collection sites 
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Figure 5.2 The median and 25th-75th percentile of pfmdr1 copy number at Pailin, Kg. 
Seila, Chumkiri, Memut, and Rattanakiri in Cambodia. The sample size at each site is: 
111 at Pailin, 10 at Kg. Seila, 69 at Chumkiri, 160 at Memut, and 78 at Rattanakiri. 
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Figure 5.3 Distribution of mutant genotypes at pfmdr1 codons 86, 184, 1034, and 1042 
CHAPTER VI: 
SUMMARY AND FUTURE DIRECTIONS 
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Falciparum malaria is a devastating illness that has a profound public health impact in the 
developing world. One of the challenges in the control of malaria is drug resistance. By 
having an effective and timely monitoring system of drug efficacy, policy makers can make 
educated decisions about what drug combinations to use and what populations to target for 
interventions. One method to increase the coverage of the current in vivo efficacy monitoring 
system is to use molecular markers of drug resistance. However, before molecular markers 
can be used, their association with clinical resistance should be established. To this end, we 
conducted two studies to estimate the effect of molecular markers and treatment failure. In 
addition, we conducted a cross-sectional study to determine the geographic distribution of 
molecular markers of mefloquine resistance. 
RUTSHURU IN VIVO EFFICACY STUDY 
The main purpose of this study was to estimate the relationship between dhfr and dhps
mutations and SP treatment failure in Rutshuru, DRC. Clinical samples and data from an in 
vivo efficacy study were used to achieve this goal. dhps mutations 437 and 540 were found 
to be more strongly related to treatment failure than dhfr-59. In addition, there were 
significant interactions between the dhps mutations: a mutation at dhps-581 was preventive 
except in the presence of dhps-437 mutation, when it had no effect on treatment failure. 
Mutations at dhps-540 and dhps-437 appear to be antagonistic, as the effect of the two 
mutations together was less than each mutation alone. In addition, the interaction term 
between these two mutations was significant (p=0.023). 
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These results are consistent with many studies that have previously shown that dhps 
mutations are associated with SP treatment failure (80, 82, 84, 87-90). However, no other 
study has investigated the interaction between individual mutations. It would be interesting to 
see if the antagonism between dhps-437 and dhps-540 is present in other regions. This result 
should also be confirmed in transfection experiments.  
The effect of dhps-437 and –540 on treatment failure differed by parasitemia. In children 
with parasitemia less than 45,000 parasites / µl, the presence of both dhps-437 and 540 
mutations was associated with a 16% (95%CI: -3.5%, 36%) greater absolute risk of treatment 
failure than having neither mutation. In children with parasitemia greater than 45,000 
parasites / µl, the presence of both mutation had a greater absolute risk of 51% (95%CI: 34%, 
67%) compared to having neither mutation. 
The greater effect of dhps-437 and -540 mutations in children with parasitemias greater 
than 45,000 parasites/µl suggests that drug resistance has a greater impact on people with 
more severe disease. By understanding what sub-group of people are hardest hit by drug 
resistance, interventions can be more accurately targeted. For example, if there are limited 
supplies of a certain second line antimalarial drug, then it might be most effective to use it 
only in people with severe disease. In addition, effect modification could be one reason why 
the effect of mutations on treatment failure appears to vary by region. Therefore, if molecular 
markers are going to be used for surveillance of resistance, a better understanding of the 
covariates that modify this relationship in the individual and at the population level is greatly 
needed.  
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PAILIN IN VIVO EFFICACY STUDY 
The purpose of this study was to estimate the relationship between genetic changes in  
pfmdr1 and recrudesesence after mefloquine-artesunate therapy. To achieve this goal, clinical 
samples and data were used from an in vivo efficacy study in Pailin, Cambodia. pfmdr1 copy 
number was strongly associated with time to recrudescence (HR = 8.30, 95%CI: 2.60, 26.43).  
However, pfmdr1 haplotype was not associated with time to recrudescence. pfmdr1 copy 
number was higher when there was recurrence of disease than before mefloquine-artesunate 
treatment was given. This suggests that mefloquine-artesunate treatment is selecting for 
increased pfmdr1 copy number. The parasite clearance time observed in this study was longer 
than reports from other areas. However, pfmdr1 copy number and haplotype were not related 
to parasite clearance time. This suggests that other mechanisms of resistance other than 
pfmdr1 are important in this area. Overall, these results are consistent with a previous study 
that investigated the role of pfmdr1 copy number on recrudescence after mefloquine-
artesunate and with another study on mefloquine monotherapy (104, 107). pfmdr1 copy 
number, but not haplotype, might be an effective monitoring tool for mefloquine-artesunate 
resistance. 
 
CAMBODIAN CROSS-SECTIONAL STUDY 
The main purpose of this study was to determine the geographic variation in pfmdr1 in 
Cambodia. pfmdr1 copy number was found to vary substantially by region. pfmdr1 copy 
number was higher in Pailin, which has a 82% cure rate, than in Rattanakiri, which has a 
100% cure rate. High pfmdr1 copy number was also found at Chumkiri, which is in an area 
not previously known for mefloquine resistance. Because of this finding, an in vivo efficacy 
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study has been scheduled for Chumkiri to confirm these results. This study demonstrates how 
using molecular makers for surveillance complements an in vivo efficacy monitoring system. 
 
LIMITATIONS AND STRENGTHS 
 These studies had several limitations. One of the main limitations of all the studies is the 
small sample size. The Rutshuru and Pailin studies had 212 and 80 samples, respectively, 
available for genotyping. This small number translates into imprecise estimates of effect. In 
addition, these results are strongly influenced by chance. The small sample size restricted 
what comparisons could be made, such as how the effect of pfmdr1 haplotype IV in the 
Pailin study could not be estimated because only four samples had this genotype. This small 
sample size also limits the power of finding effect measure modification. In the Cambodian 
cross-sectional study, the limited sample size affected the precision of the prevalence 
estimates of increased copy number. However, when compared to other studies in the field, 
the sample sizes of these studies are above average. Therefore, the problems of reduced 
precision and power and chance playing a large role are almost universal in this field. 
 Another limitation is the potential exposure misclassification. The relative proportion of 
genetic clones of P. falciparum present in the peripheral circulatory system varies (145). 
Therefore, it is possible that an infection contains a particular genetic variant yet it is not 
present in the peripheral blood when the sample is taken. Another issue is that these assays 
might not be sensitive enough to detect a mutation even when it is in the peripheral blood.  P. 
falciparum infections do contain minor variants that are not detected by standard real-time 
PCR or nested PCR methods (188, 189).  In HIV infection, minor variants have been shown 
to be clinically relevant (190, 191). However, it is unknown whether minor variants in P. 
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falciparum infections are involved in clinical resistance. These issues are also universal in 
this field. 
 Outcome misclassification is another possible source of bias, especially in the Rutshuru 
study. The current recommendation for in vivo efficacy studies involving SP is that subjects 
should be followed for at least 28 days to capture all treatment failures (32). The Rutshuru 
only had 14 days of follow-up. Therefore, it is very likely that some subjects classified as 
having an adequate clinical and parasitological response at day 14 had a recurrence of 
parasitemia later on. Another complication of the Rutshuru study is that the treatment failures 
were not PCR corrected for re-infections. The actual impact of this misclassification is 
probably small because re-infections within 14 days of treatment are rare. (The accuracy of 
assuming there are no re-infections within 14 days has not been assessed). Very few studies 
actually PCR correct treatment failures at or before 14  days. None of the studies that PCR 
corrected presented their results so that sensitivities and specificities can be calculated). 
Another complication of the Rutshuru study was the high number of exclusions, mostly due 
to loss to follow-up. However, sensitivity analysis showed that the impact of the exclusion of 
17 children had a minimal impact on the results. 
 One last issue is whether  these results are generalizable. In Rutshuru, 25% of the subjects 
were underweight and therefore it is not known whether these results are generalizable to 
healthier populations. Both in vivo studies had stringent enrollment criteria (such as certain 
age restrictions, and having no signs of severe disease or mixed infections). Therefore, it is 
not known whether these results would apply to the general population.   
 These studies also have several strengths. In all three studies, clinical samples were 
directly genotyped. In contrast, in many studies, the samples are cultured before genotyping 
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in order to have a more reliable yield of DNA. Genotyping cultured samples can result in 
exposure misclassification as P. falciparum genotypes has been shown to change when 
samples are adapted to culture (58). In addition, assays based on real-time PCR have less 
false positives and greater sensitivity than nested PCR (which is the standard method of 
genotyping) (134). 
 The Pailin study, the outcome was reliably assessed, as the 42 day follow-up most likely 
captured most instances of treatment failure. All recurrences of parasitemia were PCR 
corrected. While 10 people were lost to follow-up, everyone was followed for at least 14 
days. 
FUTURE DIRECTIONS 
 The Rutshuru and Pailin studies clearly show that molecular markers of resistance are 
related to clinical outcome. The Cambodian cross-sectional study demonstrated how the use 
of molecular markers for surveillance can be implemented. What are the other issues that 
need to be addressed before countries can implement surveillance of molecular markers? 
 One of the main questions that needs to be addressed is whether the effect of molecular 
markers is constant over a geographical area. While some studies have found that the effect 
of molecular markers is constant (192, 193), others have not (76, 133). Therefore, to ensure 
that the prevalence of increased pfmdr1 copy number is truly reflective of the treatment 
failure rate in an area, the constancy of the effect of pfmdr1 copy number of treatment failure 
should be established. 
 Another issue that needs to be addressed before molecular markers can be successfully 
implemented is that dhfr/dhps and pfmdr1 do not have perfect sensitivity and specificity in 
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predicting outcome. One possible reason for this discrepancy is that we do not fully 
understand all the determinants of treatment failure (which can be used to better predict 
treatment failure). Another possibility is that we are not accurately measuring resistance. 
Other genetic changes might be involved in conferring resistance (such as modification of the 
transcription and translation of dhfr/dhps and pfmdr1 or completely different genes). Also, 
the current assays are not sensitive enough to pick up minor variants of a clinical sample, 
which might be playing a role in resistance.  Future studies on molecular markers and 
treatment failure should focus on increasing the accuracy of detection of molecular markers 
(either by taking more than one blood sample or by using techniques that are more sensitive 
to picking up minor variants).  
 In areas where in vivo studies are feasible, molecular markers should not replace the in 
vivo monitoring. The in vivo efficacy study produces results that are more easily 
interpretable, and therefore more likely to be used by policy makers. However, molecular 
markers have great potential to complement the current surveillance system for drug efficacy. 
Measuring the prevalence of molecular markers is much easier than conducting an in vivo 
efficacy trial (as no follow-up of subjects is needed). Therefore, molecular markers can be 
used to investigate drug efficacy in areas outside of sentinel surveillance sites. For example, 
in Cambodia, increased pfmdr1 copy number was found in a site not previously known to 
have drug resistance. Molecular markers can help determine what areas need to be 
investigated further for drug resistance, and therefore lead to a more efficient and effective 
use of the in vivo efficacy study.  
Molecular markers can be used to estimate the level of resistance in unstable areas where 
in vivo efficacy studies are unfeasible(153, 154). For example, the prevalence of pfcrt, dhfr, 
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and dhps mutations in an area of political unrest in Mali were used to determine what 
antimalarials should be used in this area (154). In DRC, measuring the prevalence of dhfr and 
dhps mutations might provide a way to measure resistance in the politically unstable areas of 
the country.   
 In addition, molecular markers can be used to track the emergence of resistance and to 
evaluate the effect of various interventions on the selection of resistance. For example, 
intermittent presumptive treatment with  SP  in Ghana was associated with an increase in 
dhfr and dhps mutations, which strongly suggests this preventive strategy facilitates the 
emergence of resistance(194). Molecular markers have also been used to evaluate the impact 
of antimalarials with different half-lives and the use of bednets on the selection of resistance 
(195, 196).  
 In summary, molecular markers have great potential to expand surveillance of resistance 
and to decrease the impact of malaria in the developing world.  
APPENDIX A: 
INCLUSION/EXCLUSION CHECKLIST AND SUBJECT INFORMATION FORM 
FROM THE CAMBODIAN CROSS-SECTIONAL STUDY 
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Detection of Genetic Mutations Associated with Drug Resistance  
in P. falciparum Isolates from Cambodia by Real-Time PCR 
 
INCLUSION/EXCLUSION CRITERIA CHECK LIST 
1. P. falciparum positive (Giemsa blood smear or rapid test*)    Yes         No 
 
2. Age >=18 years old        Yes         No 
 
3. No evidence of severe/complicated malaria      Yes         No 
 requiring prompt management for life support 
 
4. No history of bleeding tendency      Yes         No 
 
5. The study has been explained to the volunteer     Yes         No 
 
6. The consent form has been signed      Yes         No 
 
----------------------------------- 
If the answer is “No” to one or more of the above questions, the patient is ineligible for inclusion. 
* To be confirmed by Giemsa blood smear. 
 
__________________________   _______________ 
Investigator’s initials     Date 
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Detection of Genetic Mutations Associated with Drug Resistance  
in P. falciparum Isolates from Cambodia by Real-Time PCR 
 
SUBJECT INFORMATION FORM 
Site:       
 Date:        
 
Baseline Demographics
Age (in years): Sex (circle one):  
 
Current residence: Village/District:______________________ 
 
Province:__________________________ 
 
Baseline Malaria Data
Number of illnesses believed due to malaria in past 12 months: 
(Circle one) 
 
Number episodes of smear positive malaria in past 12 months:   
(Circle one) 
 
Date of last drug therapy for malaria:   
(Circle one) 
 
I.     ___________       __  __ / __  __ / __  __
       D   D   M   M    Y   Y
  ____  ____  
  1. Male       2. Female
0       1       2       3       >3       9. unknown
   0        1        2        3        >3        9 unknown
<1 month >=1 month Never
         1               2              3
Barcode ID
___________
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Treatment received in  
the last one month: 
(circle all that apply)  
 
   1.chloroquine     2. SP (Fansidar)     3. quinine      4. mefloquine       5. primaquine
   6. doxycycline/    7. artesunate     8. other________________   9. unknown   10. None
tetracycline
121
 
Detection of Genetic Mutations Associated with Drug Resistance  
in P. falciparum Isolates from Cambodia by Real-Time PCR 
 
SUBJECT INFORMATION FORM (continued) 
 
Feeling ill for how many days:  
(Circle one) 
 
Symptoms: 
(Circle all reported) 
 
Blood Smear Review (by NAMRU-2) Result: 
P. falciparum confirmed    
 
P. falciparum Asexual Parasite Count: 
 OR 
 
P. falciparum Sexual Parasite Count:  
 
Presence of Non-P. falciparum   If Yes:  
 
Interviewer's Signature _____________________________ 
 
(Name   _________________________________________) 
 
On-site Investigator's Signature  ______________________________ 
 
(Name   ________________________________________________) 
 
*Pv=P. vivax, Pm= P. malariae, Po= P. ovalae 
   0 (asymptomatic)
   1       2       3       4       5       >5       9.unknown
1. Headache     2. Myalgias     3. Chills/Rigors      4. Malaise
   5. Vomiting     6. Diarrhea       7. Cough      8. Fever or History of fever
________  /500 WBC ______  /5,000 RBC 
1. Yes       2. No 
________  /500 WBC
1. Yes       2. No Pv      Pm        Po*
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APPENDIX B: 
RAPID REAL-TIME PCR GENOTYPING OF MUTATIONS ASSOCIATED WITH 
SULFADOXINE-PYRIMETHAMINE RESISTANCE IN PLASMODIUM 
FALCIPARUM 
 
by 
Alisa P. Alker, Victor Mwapasa, and Steven R. Meshnick 
Published in Antimicrobial Agents and Chemotherapy 48(8): 2924-9. 
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ABSTRACT 
Sulfadoxine-pyrimethamine (SP) -resistance of Plasmodium falciparum is an emerging 
public health threat. Resistance to these drugs is associated with point mutations in the genes 
encoding dihydropteroate synthase (dhps) and dihydrofolate reductase (dhfr). We describe an 
assay using real-time PCR and sequence specific probes that detects these mutations. Using 
DNA from plasmids, cultured strains, and clinical samples, real-time PCR could distinguish 
four dhps polymorphisms (codons 437, 540, 581, and 613) and 3 dhfr polymorphisms 
(codons 51, 59, and 108). This assay is rapid and sensitive, with a detection limit of 10 copies 
in most cases. This assay is amenable to large-scale studies of drug resistance. 
 
INTRODUCTION 
 Malaria is a major public health threat, causing millions of deaths per year. One of the 
greatest challenges in the control of malaria is drug resistance, which has contributed to its 
re-emergence and spread (25). Currently, chloroquine resistance in Plasmodium falciparum 
is nearly universal; because of chloroquine resistance, five African countries have switched 
to sulfadoxine-pyrimethamine (SP) as their first-line antimalarial (25). However, resistance 
to SP is spreading.     
 Sulfadoxine and pyrimethamine inhibit dihydropteroate synthase (dhps) and dihydrofolate 
reductase (dhfr), respectively, which are two enzymes involved in folate biosynthesis. SP 
resistance is conferred by single nucleotide changes in either enzyme, and increases as 
mutations accumulate ((70) and references therein). For dhfr, the mutations 50-Arg, 51-Ile, 
59-Arg and 108-Asn have been strongly associated with in vitro and in vivo resistance and 
are correlated with SP usage (75, 83, 85, 197). Mutations in dhps (436-Ala, 436-Phe, 437-
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Gly, 540-Lys, 581-Gly, 613-Thr and 613-Ser) have also been associated with in vitro and in 
vivo resistance, though they have a weaker relationship with SP usage than dhfr mutations 
(74, 75, 83, 197-199). Other dhfr polymorphisms are more closely associated with 
cycloguanil resistance (16-Val and 108-Thr) (66).  
 Surveillance for antimalarial drug resistance is usually done using in vitro or in vivo 
methods.  In vitro methods involve the culturing of malaria parasites, which is difficult and 
requires skilled technicians and tissue culture facilities.  In vivo methods require patients to 
be followed up for at least 14 days, which is often challenging in field conditions. Thus, new 
surveillance tools are needed. Numerous studies, using standard PCR methods, have shown 
that dhps and dhfr mutations are closely associated with SP resistance. However, the 
usefulness of these assays is restricted due to difficulty, cost, high risk for contamination, and 
the inability to pick up low prevalent genotypes in a mixed sample (200). Real-time PCR, on 
the other hand, is simpler, and less prone to contamination. The purpose of this study is to 
develop a real-time PCR assay for dhps and dhfr mutations.     
Real-time PCR Minor Groove Binding (MGB) probes provide a relatively inexpensive and 
sensitive way to detect single nucleotide polymorphisms (SNPs) in a large number of 
samples (144, 201).  MGB probes are designed to hybridize to an internal region of the PCR 
amplicon, thereby providing another level of specificity beyond the site-specific primers. 
When the Taq DNA polymerase cleaves the probe from the 5’ end, the fluorophore is 
released from the quencher, allowing it to fluoresce. The increase in fluorescence over time 
can be measured using a real-time PCR thermocycler. Single base differences between MGB 
probes and DNA cause the melting temperature to decrease significantly, which decreases 
the efficiency of probe hybridization (143, 144). Allelic discrimination is achieved by putting 
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in competition two probes complementary to wild type and mutant alleles, which are attached 
to different fluorophores (144).  The risk for contamination is much lower in this technique, 
because there is no transfer of material between the addition of the DNA and the acquisition 
of the results (202). This technique has been used for allelic discrimination in humans, and a 
similar technique has been used to identify alleles that confer drug resistance in bacteria (85, 
203, 204). 
 The impending loss of SP effectiveness in Africa, due to drug resistance, could have 
calamitous consequences. Partnering SP with another antimalarial like artesunate might 
preserve SP effectiveness by delaying the onset of SP resistance.  In order to measure the 
effects of combination chemotherapy on the development of SP resistance in Africa, we 
attempted to develop real-time PCR assays for the 3 dhfr polymorphisms (51-Ile, 59-Arg, 
108-Asn) and 5 dhps polymorphisms (436-Ala, 437-Gly, 540-Lys, 581-Gly, 613-Ser) 
reported from Africa.  
MATERIALS AND METHODS 
DNA 
Six dhps plasmids (MRA-189 through MRA-194) and 5 dhfr plasmid (MRA-195 through 
MRA-199) contained in Escherichia coli were obtained from the Malaria Reagent Repository 
Resource (http://www.malaria.mr4.org/ and references therein), containing the wild type 
sequences and the most important mutations for each gene. The E. coli clones were grown on 
LB medium (1% tryptone, 0.5% yeast extract, 1.5% agarose in dI H20) with 50 µg/ml 
ampicillin. The plasmids were extracted and purified using the Promega Wizard Plus 
minipreps DNA purification system (Promega, Madison, WI, USA). P. falciparum strain 
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3D7 parasites were kindly provided by Jesse Kwiek, Duke University. DNA was extracted 
using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). DNA from six strains of P. 
falciparum (Dd2, HB3, W2, FCR3, K1,VI/S) was obtained from Malaria Reagent Repository 
(see citation above).  
Clinical samples of malaria parasites were obtained from a subgroup of pregnant women 
enrolled in a study investigating the effect of maternal malarial infection on mother-to-child 
transmission of HIV. Details of the study, which commenced in December 2000, have been 
reported elsewhere (205). Briefly, consent was sought from women in their late third 
trimester of pregnancy before the onset of active labor. Peripheral blood samples were drawn 
to screen for malaria, using thick blood smear microscopy, and to detect HIV infection using 
Rapid Antibody Tests. All HIV-infected women and a subset of HIV-uninfected were 
enrolled in that study. For this current study, 24 clinical samples were genotyped: 21 from 
HIV and malaria-infected women, one from a parasitemic HIV-uninfected woman, and two 
controls samples from HIV-infected women who were not parasitemic. With the exception of 
one HIV-infected woman, all women reported taking at least one dose of sulfadoxine-
pyrimethamine during the antenatal period.  
Peripheral blood samples were centrifuged, and the plasma and packed cell fractions were 
stored at –800 Celsius. Subsequently, frozen packed cells were thawed and a few drops were 
transferred on filter paper. These were shipped to University of North Carolina at Chapel 
Hill, where DNA extraction was performed using the QIAamp DNA Mini Kit (Qiagen, 
Hilden, Germany). 
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Primers and probes 
All primers and probes in this study were designed using Primer Express software 
(Applied Biosystems, Courtaboeuf, France), using the defaults of the program, except that 
the minimum GC % was lowered to 20% due to the AT-rich nature of the P. falciparum 
genome. P. falciparum strain 3D7 sequences for dhfr (accession number:AF248537) and 
dhps (accession number: AF250167) were used in probe and primer design. When designing 
the primers and probes, it was assumed that all codons within the amplicon were wild type 
except for the SNP of interest. All primers were synthesized  by Qiagen (Hilden, Germany). 
The probes were synthesized by Applied Biosystems (Foster City, CA) with the fluorophores 
FAM (6-carboxyfluorescein) linked to the 5’ position of all wild type probes and VIC 
(chemical name not released by Applied Biosystems) linked the 5’ position of all mutant 
probes.  A non-fluorescent quencher and a minor groove binder were linked to the 3’ ends of 
all probes (chemical names not released by Applied Biosystems).   
 
Real-time PCR  
 PCR reactions were carried out in duplicate in 25 Rl final volume containing 12.5 Rl
Universal PCR Master Mix, 5 Rl DNA, forward and reverse primers at various 
concentrations, and both mutant and wild type probes at a final concentration of 200 nM. 
Optimal primer concentrations were determined by running reactions at all combinations of 
the forward and reverse probe at 300, 500, and 900 nM (Table B.1). All reactions were run 
on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems) using the default 
settings; they were initially denatured at 95 ºC for 10 minutes and cycled 40 times, with each 
cycle consisting of 95 ºC for 15 s and 60 ºC for 60 s.  
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 Data were transferred into Microsoft Excel ver 2002, where baseline (minimum) 
fluorescence was subtracted and replicates were averaged. To determine the detection limit 
for the wild type and mutant probes, ten-fold dilutions of the relevant plasmids were run in 
triplicate. The detection limit was taken as the lowest copy number where the standard 
deviation of the fluorescence of the wild type and mutant genotype did not overlap. To assess 
the compatibility of this assay with mixed samples, two primer -probe sets (dhfr-51, and dhfr-
59) were run using DNA from different proportions of wild type and mutant plasmids (0:1, 
1:9, 2:8, 5:5, 8:2, 9:1, 1:0). A total of 10,000 copies of plasmid DNA was used in each 
reaction.
To determine the specificity of the primer-probe sets, and to ensure their compatibility 
with genomic DNA, seven strains of P.  falciparum (3D7, Dd2, FCR3, HB3, K1, VI/S, W2) 
were genotyped using real-time PCR. The dhfr and dhps genotypes of these strains, presented 
in Table B.2, have been previously reported (67, 69, 206, 207). Real-time PCR was 
performed as described above except that only 1 µl of DNA was used per reaction. The 
genotype was determined by visually comparing the change in fluorescence of the wild type 
and mutant probes.  
Validation of Method by Genotyping Clinical Samples
The first step in genotyping the clinical samples involved using real-time PCR to detect 
the lactate dehydrogenase (ldh) gene in the conditions described previously (99). Serial 
dilutions of P. falciparum 3D7 DNA at known concentration were run on the same plate as 
the clinical samples. A standard curve of the 3D7 DNA was constructed and used to 
extrapolate the DNA concentration of the clinical samples. P.  falciparum DNA was not 
detected in the two control samples from non-parasitemic women and therefore were not 
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processed further. The remaining 22 samples were genotyped by real-time PCR using the 
optimal primer and probe concentrations (Table B.1). The amount of DNA added per 
reaction varied (1-3 µl) depending on the detection limit of the primer-probe set and the 
concentration of the sample. Samples of low concentration were run for 45 cycles instead of 
40 cycles. Each plate contained DNA from P. falciparum strains at relevant concentrations to 
act as wild type and mutant controls.  
 The genotype was determined by comparing the cycle threshold (CT) values of the wild 
type and mutant probe for each sample. The CT is the number of PCR cycles needed before 
the fluorescent signal surpasses a certain threshold (usually 20-40% of maximum).The more 
DNA of a specific genotype, the smaller the CT for that genotype-specific probe. For 
example, a sample was deemed to be wild type when the wild type probe CT was less than 
the mutant probe CT and the difference was similar to that seen with the wild type plasmid 
DNA. A sample was considered to be mixed when the CT’s of both wild type and mutant 
probes were closer and intermediate between the patterns seen for pure and wild type plasmid 
DNA. 
Five clinical samples were chosen to be sequenced based on the following criteria: 1. Real-
time results were available for all seven SNP’s  2. Both wild type and mutant genotypes were 
included, when possible and 3. If the sample was mixed, a dominant genotype could be 
distinguished from real-time PCR (which eliminated 3 samples from consideration). 
 
Sequencing 
The five clinical samples were amplified using the same primers as in the MGB real-time 
PCR assay. Reactions were carried out in 25 Rl final volume containing 12.5 Rl SYBR Green 
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Master Mix, 1 Rl DNA, and forward and reverse primers at 300nM. All reactions were run on 
an ABI PRISM 7000 Sequence Detection System (Applied Biosystems) using the default 
settings with the dissociation step added at 60bC. The dissociation curves were examined to 
ensure that each reaction contained only one product. The resulting amplicon was purified 
using Centri Spin-10 Columns (Princeton Separations, Adelphia, NJ). Sequencing was 
performed at the University of North Carolina Sequencing Core using the ABI PRISMTM 
BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems).   
 
RESULTS 
Real-time PCR was both sensitive and specific for P.  falciparum dhfr and dhps genetic 
polymorphisms.  The reaction conditions were effective for a wide range of P. falciparum 
DNA concentrations and had detection limits ranging from 10 to 1000 copies (Table B.1).  
For the 7 polymorphisms shown in Figure B.1, the wild type probe generated fluorescence 
with the wild type sequence but not the mutant sequence, while the mutant probe generated 
fluorescence with the mutant sequence but not the wild type sequence. No amplification was 
ever seen in the absence of template (data not shown).  
Background fluorescence (wild type probe with mutant sequence and vice versa) was 
minimal, except in the case of the dhfr wild type (59-Cys) probe.  However, this background 
reaction did not prevent genotype determination, since the wild type sequence still clearly 
amplified more rapidly than the mutant sequence. The original batch of the 59-Cys probe had 
a weak signal but provided sufficient discriminating ability. Subsequent batches of 59 wild 
type probe from Applied Biosystems had a much stronger signal and more background 
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binding. However, the discriminating ability was similar to the original batch (data not 
shown).  
Attempts to distinguish polymorphisms at dhps-436 were unsuccessful 
 Real-time PCR was successful in determining the genotype of the P. falciparum strains for 
dhfr-51, dhfr-59, dhps-540, and dhps-581. For dhfr-108, the probe was designed to detect the 
asparagine mutant. Yet, the mutant probe also picked up the 108-Thr mutant, though the CT 
value was less than that for 108-Asn. Similarly, the dhps-613 mutant probe, designed to 
identify the 613-Ser mutation, also bound to the 613-Thr mutation. However, in this case the 
CT values for the mutant probe was similar for both 613-Ser and 613-Thr and therefore they 
could not be distinguished. In both cases, wild type could be distinguished from mutant 
sequences. The genotyping of dhps-437 was successful in the presence of 436-Ser. There was 
no binding of the wild type or mutant probe for dhps-437 in the presence of the 436-Ala and 
436-Phe mutations.  
 For two of the loci (dhfr-51, dhfr-59), various mixtures of wild type and mutant plasmids 
were prepared and then PCR-amplified. In all cases, a mixture could be differentiated from a 
pure sample if the minor component was present at > 10% (Figure B.2). 
This method was validated using clinical samples. Complete dhfr genotypes were 
determined using real-time PCR for all 22 samples taken from parasitemic women. An 
example of the real-time amplification of a clinical sample is shown in Figure B.3. In regards 
to dhps, 21 samples were fully genotyped; the dhps-540 genotype could not be ascertained 
for one sample. The five selected clinical samples were successfully sequenced for all seven 
loci. For the 3 dhfr loci and 4 dhps loci, there was a 100% concordance of the dominant 
genotype between sequencing and real-time PCR (Table B.2). Sequencing was unable to 
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detect mixed infections that were identified using real-time PCR. 
 
DISCUSSION 
 We describe a real-time PCR assay to detect polymorphisms associated with drug 
resistance in P. falciparum. We could successfully discriminate between wild type and 
resistant alleles in 7 of the 8 loci important in Africa. 
 As a surveillance tool, real-time PCR has certain advantages over classical PCR.  First, the 
assay is rapid and can reliably distinguish between two alleles after a single 3-hour 
experiment.  There is no need to run gels after the reaction.  Second, the risk of 
contamination is far lower than with nested PCR because it is a closed tube reaction. Third, 
the assay can be automated and processed in a high-throughput fashion. The initial cost of 
real-time PCR (consisting of buying the actual machine and optimizing the assay) is higher 
than normal PCR and may not be available in all malaria-endemic countries. However, part 
of this cost could be made up if used for high throughput processing as reagents for a single 
reaction cost between $0.40 and $2.  
 Recently, a fluorogenic PCR assay using FRET probes was developed to genotype codons 
50-60 of dhfr in P. falciparum (208). This technique has a similar advantage of low risk of 
contamination as the assay we describe. However, it has yet to be expanded to detect the 
other important mutations associated with drug resistance. 
 There are several limitations to the real-time PCR system described here.  The most 
serious deficiency is its inability to distinguish alleles at position 436, and alleles at 437 when 
there is a mutation at the 436 position. However, the 436 mutations are rare in Africa and 
appear not to be involved in the “quintuple mutants” (108-Asn, 51-Ile, 59-Arg in dhfr, and 
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437-Gly and 540-Glu in dhps) that are especially important in Africa (70). Also, while real-
time PCR can theoretically distinguish 3 or more alleles, we were not able to accomplish this 
at dhfr positions 108 and 613. While we can distinguish wild type from mutants at dhfr 
position 108, we cannot distinguish between 108-Asn, associated with SP resistance, and 
108-Thr, associated with cycloguanil resistance. Thus, further work is needed to enable the 
detection of these other polymorphisms. In addition, it should be noted that the detection 
limit differs among the primer-probe sets. This could potentially lead to an under-
representation of certain genotypes. Nevertheless, given the advantages of this method, real-
time PCR measurement of 7 dhfr and dhps polymorphisms could serve as a useful tool for 
the surveillance of SP-resistant malaria.  
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TABLE B.1 Real-time primer and probe sequences and optimal concentrations*
Target Oligonucleotides (5'  3') 
Final 
Conc.
Detection 
Limit 
 (nM) (copies/rxn) 
dhfr-51 
F:TGAGGTTTTTAATAACTACACATTTAGAGGT
CT F:300
R: TATCATTTACATTATCCACAGTTTCTTTGTT R:300
WTP: AATGTAATTCCCTAGATATG  WT: 10 
 MP: AAATGTATTTCCCTAGATATG  M: 10 
dhfr-59 F: Same as dhfr-51 F:300
R: Same as dhfr-51 R:500
WTP: AATATTTTTGTGCAGTTACA  WT: 100 
 MP: TGAAATATTTTCGTGCAGTTA  M: 10 
dhfr-108 F:TGGATAATGTAAATGATATGCCTAATTCTAA F:300
R:AATCTTCTTTTTTTAAGGTTCTAGACAATATA
ACA R:300
WTP: AGAACAAGCTGGGAAA  WT: 1000 
 MP: AGAACAAACTGGGAAAG  M: 10 
dhps-437 F: TGAAATGATAAATGAAGGTGCTAGTGT F:900
R:AATACAGGTACTACTAAATCTCTTTCACTAA
TTTTT R:900
WTP: AGAATCCTCTGCTCCT  WT: 10 
 MP: AATCCTCTGGTCCTTT  M: 10 
dhps-436 Primers and WT probe same as dhps-437   
 MP: AGAATCCGCTGTC  Unsuccessful 
dhps-540 F: AATGCATAAAAGAGGAAATCCACAT F:300
R: TCGCAAATCCTAATCCAATATCAA R:300
WTP: CAATGGATAAACTAACAAA  WT: 10 
 MP: AATGGATGAACTAACAAA  M: 10 
dhps-581 F: CCTCGTTATAGGATACTATTTGATATTGGAT F:500
R: TGGGCAATAAATCTTTTTCTTGAATA R:300
WTP: ATTTGCGAAGAAAC  WT: 10 
 MP: ATTTGGGAAGAAACAT  M: 100 
dhps-613 F: TGGATTAGGATTTGCGAAGAAAC F:500
R:GTTGTGTATTTATTACAACATTTTGATCATTC R:300
WTP: ATTTATTGCCCATTGCAT  WT: 10 
 MP: AGATTTATTTCCCATTGCA (Serine)  M: 10 
 MP: AGATTTATTACCCATTGCA (Threonine)  Unsuccessful 
*The SNP is underlined in the probes.  F= forward primer, R=reverse primer, WTP=wild type 
probe, MP=mutant probe. 
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TABLE B.2 dhfr and dhps genotypes for P. falciparum strains and clinical samples, as 
determined by sequencing*
dhfr dhps
Strain/Sample 51 59 108 436 437 540 581 613 
Strains 3D7 Asn Cys Ser Ser Gly Lys Ala Ala 
Dd2 Ile Arg Asn Phe Gly Lys Ala Ser 
HB3 Asn Cys Asn Ser Ala Lys Ala Ala 
W2 Ile Arg Asn Phe Gly Lys Ala Ser 
FCR3 Asn Cys Thr Ser Ala Lys Ala Ala 
K1 Asn Arg Asn Ser Gly Lys Gly Ala 
VI/S Ile Arg Asn Phe Gly Lys Ala Thr 
Clinical  CS1318 Ile Arg Asn Ser Ala Lys* Ala Ala 
Samples CS1338 Ile* Arg Asn Ser Gly Glu Ala* Ala 
CS1452 Ile Arg Asn Ser Ala* Glu Gly* Ala 
CS1648 Ile Cys Asn Ser Gly Glu Ala Ala 
CS1915 Ile* Arg Asn Ser Gly Glu Ala Ala 
Reference WT Asn Cys Ser Ser Ala Lys Ala Ala 
M Ile Arg Asn/Thr Ala/Phe Gly Glu Gly Ser/Thr
*The last two rows portray the wild type (WT) and mutant (M) genotypes for each 
polymorphism. See text for citations. Clinical samples that were identified as mixed with 
real-time PCR are indicated with a “*”. 
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Figure B.1 Real-time PCR detection of P.  falciparum genotypes. Plasmid DNA 
containing wild type and mutant template DNA (as labeled) were amplified with mixtures of 
wild type probe (FAM labeled, solid line) and mutant probe (VIC-labeled, broken line). 
Relative fluorescence was calculated by subtracting the minimal fluorescence from each 
value. 
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Figure B.2 Real-time PCR genotyping of a mixed genotype sample. Various mixtures of 
wild type and mutant plasmid DNA were amplified. The results for the 51 VIC probe are 
presented as averages of three replicates from which the minimal fluorescence has been 
subtracted. The solid line represents a 100% mutant sample. The gray line represents a 10% 
mutant and 90% wild type sample. The broken line represents a 100% wild type sample. 
 
138
Figure B.3 Real-time PCR genotyping of 108 polymorphism in clinical sample CS1338. 
The FAM labeled probe (solid line) is designed to detect the wild type sequence. The VIC 
labeled probe, (broken line) is designed to detect the mutant sequence. The change of 
fluorescence of the two probes was compared to controls ran at similar concentrations. The 
genotype was determined to be mutant (Asn/Thr) with no wild type component. Relative 
fluorescence was calculated by subtracting the minimal fluorescence from each value. 
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ABSTRACT 
We conducted a prevalence study of mutations in Plasmodium falciparum that are 
associated with antifolate resistance in Blantyre, Malawi.  The dihydrofolate reductase (dhfr)
164-leu mutation, which confirs resistance to both pyrimethamine and chlorproguanil, was 
found in 4.7% of the samples. Previously unreported mutations in dihydropteroate synthase 
(dhps) were also found. 
 
INTRODUCTION 
Resistance to sulfadoxine-pyrimethamine (SP) in Plasmodium falciparum is conferred by 
mutations in the dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes. 
The five main mutations (“quintuple mutant”: dhfr-51, 59, 108 and dhps-437 and 540) 
strongly predict clinical outcome (70, 82). Mutations in dhfr-164, dhps-581 and dhps-613 
develop later in a population,  and are associated with increased  SP resistance  (75).  
One proposed alternative to SP is chlorproguanil-dapsone (LapDap). Both chlorproguanil 
and pyrimethamine target dhfr, and changes at codon 164 confer resistance to both drugs 
(69). This cross-resistance might limit the usefulness of LapDap in areas where SP has been 
used heavily (209). Currently in Africa, the dhfr-164 mutation is rare. Nevertheless, the 
prevalence of this mutation should be monitored where LapDap is being considered as a 
candidate therapy.  
In Malawi, SP has been the first-line agent for malaria since 1993. The quintuple mutation 
is highly prevalent: 78% of samples contained the quintuplet mutation in the Salima district 
in 2001 (210). However, subsequent mutations (dhps-613, dhps-581 and dhfr-164) have not 
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been previously reported. The purpose of this study is to determine the prevalence of 
mutations in dhfr and dhps in Blantyre, Malawi. 
 
METHODS 
Clinical samples of Plasmodium falciparum were acquired from pregnant women at 
Queen Elizabeth Hospital (Blantyre, Malawi) who were enrolled in a study investigating 
mother-to-child transmission of HIV (205). Venous blood was taken at enrollment, and  the 
plasma and packed-cell fractions were frozen at –80 °C. Malaria was screened for using 
thick-blood-smear microscopy. A random sample of the Plasmodium falciparum -positive 
samples were included in this study. 22 samples were transferred to filterpaper and processed 
as previously described (142). 68 additional samples were shipped frozen to UNC Chapel 
Hill, where DNA was extracted using the Qiamp DNA mini kit (Qiagen).  The samples for 
this study were collected between March 2001 and May 2003. In this subgroup, 15.7% report 
taking SP within the last two weeks while 85.4% report taking SP at some point during their 
pregnancy. No one reported using LapDap.  
The 22 samples from bloodspots were previously genotyped for codons 51, 59, and 108 
in dhfr and codons 437, 540, 581 and 613 in dhps (142). However, the dhfr/dhps genotype 
was reported only for 5 samples. The prevalence of the mutations in all 22 samples will be 
reported here. 
dhfr-164 was genotyped using a new real-time PCR assay. Two minor groove binder 
(MGB) probes were developed: one that detects the isoleucine (wild-type) sequence and 
another that detects the leucine (mutant) sequence (Table C.1). The primers and probes were 
synthesized by MWG Biotech (High Point, NC) and Applied Biosystems (ABI), 
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respecitively. PCR reactions were carried out in duplicate in 25 Rl reactions containing 12.5 
Rl Universal PCR Master Mix (ABI), 2 Rl DNA, forward primer at 300nM, reverse primer at 
500 nM, and both probes at 200 nM. All reactions were run on an ABI PRISM 7000 (ABI); 
they were initially denatured at 95 ºC for 10 minutes and cycled 45 times, with each cycle 
consisting of 92 ºC for 14 s and 60 ºC for 60 s. 21 samples from bloodspots and 68 samples 
from peripheral blood were tested using this assay. The results were analyzed as previously 
described (142). 
To validate this assay, genomic DNA (Dd2, HB3, W2, FCR3, K1, and VI/S from the 
Malaria Reagent Repository Resource, http://www.malaria.mr4.org/ ) was genotyped for 
dhfr-164. The assay correctly identified VI/S as mutant and the rest as wild-type. Clinical 
samples were sequenced for further validation. The amplified product from the real-time 
reaction was purified using CentriSpin-10 columns (Princeton Separations) then sequenced 
as previously described (142).  
 
RESULTS 
Of the samples from blood spots, 90.1% contained the quintuple mutation (Figure C.1). 
One sample (4.6%) contained a dhps-613 mutant component while three different samples 
(13.6%) contained a dhps-581 mutant component. These mutations were only observed in 
mixed infections. 
Because of its potential pubic health implications, dhfr-164 was genotyped in a larger 
number of samples.  Genotyping was successful for 18 out of 21 blood spot samples and 67 
out of 68 samples from stored blood. In the resulting 85 samples, four contained the dhfr-
164-leu mutation, resulting in a prevalence of 4.7% (95% confidence interval: 0, 9.2%). One 
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sample contained only the mutant dhfr-164 genotype while the rest contained a mixture of 
wild-type and mutant genotypes. The genotypes of the fully mutant sample and two wild-
type samples were confirmed with sequencing. The four samples with the dhfr-164 mutation 
also contained the quintuple mutation but were wild-type at dhps-581 and dhps-613.  
 
DISCUSSION 
In Malawi, the 14 day clinical efficacy of SP appears to have stabilized at ~80% in 
children under 5 between 1998-2002, which has been attributed to delay in emergence of the 
dhfr-164 and dhps-581 mutations (211). This is the first report of the dhfr-164, dhps-581, and 
dhps-613 mutations in clinical samples from Malawi. The presence of these mutations 
suggests resistance to SP may be increasing. 
 The presence of the dhfr-164-leu mutation is also troubling because it confers cross-
resistance to chlorproguanil (LapDap). In Africa, the dhfr-164 mutation is rarely found: 
previous reports of this mutation were from travelers, people treated with LapDap, and as a 
rare component of samples (88, 188, 189, 212, 213). In contrast, we report the dhfr-164 
mutation as a major component of samples in African women who report not taking LapDap. 
 Our screening for mutations in dhfr and dhps was restricted to pregnant women in 
Blantyre with previous SP exposure, and therefore the prevalence of these mutations in the 
general population is uncertain. In fact, recent clinical trials of LapDap in children in 
Blantyre proved effective (214, 215), suggesting that the dhfr-164 mutation remains rare. 
Surveillance  for these mutations in the general population is needed, and results must be 
related to those of in vivo efficacy studies to confirm these mutations are associated with high 
levels of  clinical SP or LapDap resistance. New technologies for SNP detection, such as 
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real-time PCR, enable the rapid screening of a large number of samples and can be employed 
for the monitoring of parasite mutations associated with drug resistance. 
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Table C.1 Sequences of primers and probes used in real-time PCR for the dhfr-164 
genotyping assay 
Type Sequence (5’3’) 
Forward primer ATC ATT AAC AAA GTT GAA GAT CTA ATA GTT TTA 
Reverse primer TCG CTA ACA GAA ATA ATT TGA TAC TCA 
Wild-type probe 6FAM-ATG TTT TAT TAT AGG AGG TTC CGT T-MGB 
Mutant probe VIC-ATG TTT TAT TTT AGG AGG TTC CGT T-MGB 
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Figure C.1 The prevalence of mutant, and mixed genotypes in samples from pregnant 
women with malaria in Blanytre, Malawi. A mutant genotype is defined as: dhfr-51-Ile, dhfr-
59-Arg, dhfr-108-Asn/Thr, dhfr-164-Leu, dhps-437-Gly, dhps-540-Glu, dhps-581-Gly, dhps-
613-Ser/Thr. The sample size is 22 for all codons except for dhps-540 (n=21) and dhfr-164 
(n=85). Black = mutant and gray = mixed.  
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